>PA575078.1 JP 2023043118-A/8: RECOMBINANT FUSION PROTEINS TARGETING CD47 AND PD-L1, PREPARATION AND USE THEREOF
GCCGCCACC
>pdb|8OIN|AI Chain AI, 55S mammalian mitochondrial ribosome with mtRF1 and P-site tRNA
AATGAGACA
>PA573904.1 JP 2023021634-A/16: A fluorescently labeled nucleic acid probe
NNNNGATAN
>pdb|8OIP|AI Chain AI, 28S mammalian mitochondrial small ribosomal subunit with mtRF1 and P-site tRNA
AATGAGACA
>pdb|7MXU|B Chain B, Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' flap DNA (cf2)
NGACTAGCG
>pdb|7MXT|B Chain B, Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (cmr)
NGACTAGCG
>pdb|7MXS|B Chain B, Crystal structure of human exonuclease 1 Exo1 (WT) in complex with 5' recessed-end DNA (cr)
NGACTAGCG
>pdb|8I54|D Chain D, Lb2Cas12a RNA DNA complex
AGTGCTTTA
>pdb|7URK|D Chain D, Self-assembling DNA tensegrity triangle motif with intercalating internal Cy3 modification
NGGACATCA
>pdb|1Z1C|C Chain C, Structural Determinants of Tissue Tropism and In Vivo Pathogenicity for the Parvovirus Minute virus of Mice
ACACCAAAA
>pdb|8G9L|D Chain D, DNA initiation subcomplex of Xenopus laevis DNA polymerase alpha-primase
NGATACTGN
>pdb|8AKN|Y Chain Y, Cryo-EM structure of the proline-rich antimicrobial peptide drosocin bound to the terminating ribosome
NTATTCTAA
>pdb|7UID|C Chain C, Thyclotides peptide nucleic acid in complex with DNA
GATGTGATA
>pdb|7UID|A Chain A, Thyclotides peptide nucleic acid in complex with DNA
GATGTGATA
>pdb|8CX2|L Chain L, Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 2
NTTAAAAAT
>pdb|8CX2|K Chain K, Cryo-EM structure of human APOBEC3G/HIV-1 Vif/CBFbeta/ELOB/ELOC dimeric complex in State 2
NATAAAAAT
>pdb|8D93|D Chain D, [2T7] Self-assembling tensegrity triangle with R3 symmetry at 2.96 A resolution, update and junction cut for entry 3GBI
NGGACATCA
>PA566203.1 WO 2022270585-A/195: Combination of antisense oligomers
AACAGTGTG
>PA566202.1 WO 2022270585-A/194: Combination of antisense oligomers
AAACAGTGT
>PA566201.1 WO 2022270585-A/193: Combination of antisense oligomers
TAAACAGTG
>PA566200.1 WO 2022270585-A/192: Combination of antisense oligomers
TTAAACAGT
>PA566199.1 WO 2022270585-A/191: Combination of antisense oligomers
ATTAAACAG
>PA566198.1 WO 2022270585-A/190: Combination of antisense oligomers
GATTAAACA
>PA566197.1 WO 2022270585-A/189: Combination of antisense oligomers
AGATTAAAC
>PA566196.1 WO 2022270585-A/188: Combination of antisense oligomers
AAGATTAAA
>PA566195.1 WO 2022270585-A/187: Combination of antisense oligomers
AAAGATTAA
>PA566194.1 WO 2022270585-A/186: Combination of antisense oligomers
AAAAGATTA
>PA566193.1 WO 2022270585-A/185: Combination of antisense oligomers
GAAAAGATT
>PA566192.1 WO 2022270585-A/184: Combination of antisense oligomers
AGAAAAGAT
>PA566191.1 WO 2022270585-A/183: Combination of antisense oligomers
GAGAAAAGA
>PA566190.1 WO 2022270585-A/182: Combination of antisense oligomers
TGAGAAAAG
>PA566098.1 WO 2022270585-A/90: Combination of antisense oligomers
CACACTGTT
>PA566097.1 WO 2022270585-A/89: Combination of antisense oligomers
ACACTGTTT
>PA566096.1 WO 2022270585-A/88: Combination of antisense oligomers
CACTGTTTA
>PA566095.1 WO 2022270585-A/87: Combination of antisense oligomers
ACTGTTTAA
>PA566094.1 WO 2022270585-A/86: Combination of antisense oligomers
CTGTTTAAT
>PA566093.1 WO 2022270585-A/85: Combination of antisense oligomers
TGTTTAATC
>PA566092.1 WO 2022270585-A/84: Combination of antisense oligomers
GTTTAATCT
>PA566091.1 WO 2022270585-A/83: Combination of antisense oligomers
TTTAATCTT
>PA566090.1 WO 2022270585-A/82: Combination of antisense oligomers
TTAATCTTT
>PA566089.1 WO 2022270585-A/81: Combination of antisense oligomers
TAATCTTTT
>PA566088.1 WO 2022270585-A/80: Combination of antisense oligomers
AATCTTTTC
>PA566087.1 WO 2022270585-A/79: Combination of antisense oligomers
ATCTTTTCT
>PA566086.1 WO 2022270585-A/78: Combination of antisense oligomers
TCTTTTCTC
>PA566085.1 WO 2022270585-A/77: Combination of antisense oligomers
CTTTTCTCA
>pdb|8FIY|R Chain R, Cryo-EM structure of E. coli RNA polymerase Elongation complex in the Transcription-Translation Complex (RNAP in an anti-swiveled conformation)
NCGGACAAT
>pdb|7YFE|T Chain T, In situ structure of polymerase complex of mammalian reovirus in virion
NCGATTAGC
>pdb|6M2P|D Chain D, Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (A10-deletion mutant)
CACCTAGCG
>pdb|6M2P|C Chain C, Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (A10-deletion mutant)
CACCTAGCG
>pdb|6M2P|B Chain B, Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (A10-deletion mutant)
CACCTAGCG
>pdb|6M2P|A Chain A, Crystal structure of a NIR-emitting DNA-stabilized Ag16 nanocluster (A10-deletion mutant)
CACCTAGCG
>pdb|7OZZ|B Chain B, The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG with LNA-amide modification
CTNTCTTTG
>pdb|7OOS|B Chain B, The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG
CTNTCTTTG
>pdb|7OOO|E Chain E, The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG containing an LNA-Amide-LNA modification
CTNTCTTTG
>pdb|7OOO|B Chain B, The crystal structure of a DNA:RNA hybrid duplex sequence CTTTTCTTTG containing an LNA-Amide-LNA modification
CTNTCTTTG
>pdb|6YMJ|P Chain P, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMJ|N Chain N, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMJ|J Chain J, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMJ|G Chain G, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMJ|D Chain D, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMJ|B Chain B, Crystal structure of the SAM-SAH riboswitch with adenosine.
ATTGGAGCA
>pdb|6YMI|P Chain P, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|6YMI|N Chain N, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|6YMI|J Chain J, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|6YMI|G Chain G, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|6YMI|D Chain D, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|6YMI|B Chain B, Crystal structure of the SAM-SAH riboswitch with AMP.
ATTGGAGCA
>pdb|8CLM|C Chain C, 1.80 A crystal structure of RNA/2'-O-methyl-RNA heteroduplex
GTCTCCTAG
>pdb|8CLM|B Chain B, 1.80 A crystal structure of RNA/2'-O-methyl-RNA heteroduplex
GTCTCCTAG
>pdb|8CLM|A Chain A, 1.80 A crystal structure of RNA/2'-O-methyl-RNA heteroduplex
GTCTCCTAG
>PA564024.1 JP 2022544004-A/45: ENGINEERED NUCLEIC ACID REGULATORY ELEMENTS AND METHODS AND USES THEREOF
CATTCTACC
>PA563926.1 WO 2022239863-A/3: Antisense Oligomer
AGAAGAAGG
>PA563925.1 WO 2022239863-A/2: Antisense Oligomer
GTTCGAAAA
>pdb|2L8W|B Chain B, r(CCGCUGCGG)2 UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with two hydrogen bond pairs
CCGCTGCGG
>pdb|2L8W|A Chain A, r(CCGCUGCGG)2 UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with two hydrogen bond pairs
CCGCTGCGG
>pdb|2L8U|B Chain B, NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with one hydrogen bond pair
CCGCTGCGG
>pdb|2L8U|A Chain A, NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with one hydrogen bond pair
CCGCTGCGG
>pdb|2L8C|B Chain B, NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with zero hydrogen bond pairs
CCGCTGCGG
>pdb|2L8C|A Chain A, NMR Spectroscopy and Molecular Dynamics Simulation of r(CCGCUGCGG)2 Reveal a Dynamic UU Internal Loop Found in Myotonic Dystrophy Type 1 - UU pair with zero hydrogen bond pairs
CCGCTGCGG
>pdb|8CYM|J Chain J, [2T7+9bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 9 bp Sticky-End Linker
GTACTCGCA
>pdb|8CYM|I Chain I, [2T7+9bp Linker] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle with 9 bp Sticky-End Linker
GATGCGAGT
>pdb|8CS6|D Chain D, [AGG/CTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
CTCTGATGT
>pdb|8CS5|D Chain D, [GGA/CTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
CTCTGATGT
>pdb|8CS4|D Chain D, [AGC/GTC] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
GTCTGATGT
>pdb|8CS3|D Chain D, [CAG/TCG] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
TCGTGATGT
>pdb|8CS7|D Chain D, [CCG/CCG] Self-Assembled 3D DNA Hexagonal Tensegrity Triangle
CCGTGATGT
>pdb|7XD9|R Chain R, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD9|O Chain O, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD9|L Chain L, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD9|I Chain I, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD9|F Chain F, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD9|C Chain C, Crystal Structure of Dengue Virus serotype 2 (DENV2) Polymerase Elongation Complex (CTP Form)
NGATATAAT
>pdb|7XD8|R Chain R, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|7XD8|O Chain O, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|7XD8|L Chain L, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|7XD8|I Chain I, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|7XD8|F Chain F, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|7XD8|C Chain C, Crystal Structure of Dengue Virus Serotype 2 (DENV2) Polymerase Elongation Complex (Native Form)
NGATATAAT
>pdb|8DH5|P Chain P, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
NCGATTCCC
>pdb|8DH5|L Chain L, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
NCGATTCCC
>pdb|8DH5|H Chain H, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
NCGATTCCC
>pdb|8DH5|D Chain D, T7 RNA polymerase elongation complex with unnatural base dPa-ATP mismatch
NCGATTCCC
>pdb|8DH4|P Chain P, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
NCGATTCCC
>pdb|8DH4|L Chain L, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
TCGATTCCC
>pdb|8DH4|H Chain H, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
NCGATTCCC
>pdb|8DH4|D Chain D, T7 RNA polymerase elongation complex with unnatural base dPa-DsTP pair
NCGATTCCC
>pdb|8DH3|P Chain P, T7 RNA polymerase elongation complex with unnatural base dPa
NCGATTCCC
>pdb|8DH3|L Chain L, T7 RNA polymerase elongation complex with unnatural base dPa
NCGATTCCC
>pdb|8DH3|H Chain H, T7 RNA polymerase elongation complex with unnatural base dPa
NCGATTCCC
>pdb|8DH3|D Chain D, T7 RNA polymerase elongation complex with unnatural base dPa
NCGATTCCC
>pdb|8DH2|O Chain O, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
NCGATTCCC
>pdb|8DH2|H Chain H, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
NCGATTCCC
>pdb|8DH2|D Chain D, T7 RNA polymerase elongation complex with unnatural base dDs-ATP mismatch
NCGATTCCC
>pdb|8DH1|O Chain O, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
NCGATTCCC
>pdb|8DH1|H Chain H, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
NCGATTCCC
>pdb|8DH1|D Chain D, T7 RNA polymerase elongation complex with unnatural base dDs-PaTP pair
TCGATTCCC
>pdb|8DH0|P Chain P, T7 RNA polymerase elongation complex with unnatural base dDs
NCGATTCCC
>pdb|8DH0|H Chain H, T7 RNA polymerase elongation complex with unnatural base dDs
NCGATTCCC
>pdb|8AMN|d Chain d, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|c Chain c, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|b Chain b, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|a Chain a, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|Z Chain Z, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|Y Chain Y, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|V Chain V, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|U Chain U, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|T Chain T, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|S Chain S, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|R Chain R, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|Q Chain Q, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|P Chain P, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|O Chain O, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|N Chain N, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|M Chain M, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|L Chain L, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|K Chain K, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|J Chain J, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|I Chain I, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|H Chain H, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|G Chain G, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|F Chain F, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|E Chain E, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|D Chain D, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|C Chain C, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|B Chain B, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMN|A Chain A, Crystal structure of AUGUGGCAU duplex with strontium ions
ATGTGGCAT
>pdb|8AMM|d Chain d, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|c Chain c, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|b Chain b, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|a Chain a, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|Z Chain Z, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|Y Chain Y, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|V Chain V, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|U Chain U, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|T Chain T, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|S Chain S, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|R Chain R, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|Q Chain Q, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|P Chain P, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|O Chain O, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|N Chain N, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|M Chain M, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|L Chain L, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|K Chain K, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|J Chain J, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|I Chain I, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|H Chain H, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|G Chain G, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|F Chain F, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|E Chain E, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|D Chain D, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|C Chain C, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|B Chain B, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AMM|A Chain A, Crystal structure of AUGUGGCAU duplex with cesium ions
ATGTGGCAT
>pdb|8AML|d Chain d, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|c Chain c, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|b Chain b, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|a Chain a, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|Z Chain Z, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|Y Chain Y, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|V Chain V, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|U Chain U, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|T Chain T, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|S Chain S, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|R Chain R, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|Q Chain Q, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|P Chain P, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|O Chain O, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|N Chain N, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|M Chain M, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|L Chain L, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|K Chain K, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|J Chain J, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|I Chain I, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|H Chain H, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|G Chain G, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|F Chain F, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|E Chain E, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|D Chain D, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|C Chain C, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|B Chain B, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AML|A Chain A, Crystal structure of AUGUGGCAU duplex with cadmium ions
ATGTGGCAT
>pdb|8AMK|d Chain d, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|c Chain c, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|b Chain b, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|a Chain a, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|Z Chain Z, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|Y Chain Y, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|V Chain V, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|U Chain U, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|T Chain T, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|S Chain S, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|R Chain R, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|Q Chain Q, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|P Chain P, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|O Chain O, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|N Chain N, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|M Chain M, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|L Chain L, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|K Chain K, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|J Chain J, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|I Chain I, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|H Chain H, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|G Chain G, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|F Chain F, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|E Chain E, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|D Chain D, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|C Chain C, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|B Chain B, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMK|A Chain A, Crystal structure of AUGUGGCAU duplex crystallized in the presence of calcium ions
ATGTGGCAT
>pdb|8AMJ|B Chain B, Crystal structure of unliganded AUGUGGCAU duplex
ATGTGGCAT
>pdb|8AMJ|A Chain A, Crystal structure of unliganded AUGUGGCAU duplex
ATGTGGCAT
>pdb|8AMI|B Chain B, Crystal structure of AUGUGGCAU duplex with barium ions (model 2)
ATGTGGCAT
>pdb|8AMI|A Chain A, Crystal structure of AUGUGGCAU duplex with barium ions (model 2)
ATGTGGCAT
>pdb|8AMG|L Chain L, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|K Chain K, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|J Chain J, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|I Chain I, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|H Chain H, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|G Chain G, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|F Chain F, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|E Chain E, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|D Chain D, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|C Chain C, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|B Chain B, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>pdb|8AMG|A Chain A, Crystal structure of AUGUGGCAU duplex with barium ions (model 1)
ATGTGGCAT
>PA561476.1 WO 2022220141-A/195: Method for detecting mutant SARS-CoV-2
TTTGGTGAA
>PA561443.1 WO 2022220141-A/162: Method for detecting mutant SARS-CoV-2
CCGATGAGA
>PA561436.1 WO 2022220141-A/155: Method for detecting mutant SARS-CoV-2
CCGATGAGA
>PA561419.1 WO 2022220141-A/138: Method for detecting mutant SARS-CoV-2
CCAGTATAG
>PA561369.1 WO 2022220141-A/88: Method for detecting mutant SARS-CoV-2
TACCGGTAT
>PE006695.1 KR 1020220080012-A/2803: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TGGGAGGTC
>PE006656.1 KR 1020220080012-A/2764: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
CCAAAGCCC
>PE002352.1 KR 1020220087537-A/349: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCC
>PE002344.1 KR 1020220087537-A/333: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GGTGCATCC
>PE002336.1 KR 1020220087537-A/317: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCC
>PE002328.1 KR 1020220087537-A/301: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002308.1 KR 1020220087537-A/261: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002300.1 KR 1020220087537-A/245: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCC
>PE002292.1 KR 1020220087537-A/229: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002284.1 KR 1020220087537-A/213: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
AAGGCGTCT
>PE002276.1 KR 1020220087537-A/197: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCC
>PE002268.1 KR 1020220087537-A/181: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
ACTGCATCC
>PE002260.1 KR 1020220087537-A/165: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
ACTGCATCC
>PE002244.1 KR 1020220087537-A/133: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002236.1 KR 1020220087537-A/117: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002232.1 KR 1020220087537-A/109: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002224.1 KR 1020220087537-A/93: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCG
>PE002216.1 KR 1020220087537-A/77: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002184.1 KR 1020220087537-A/13: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
AAGGCGTCT
>PE002208.1 KR 1020220087537-A/61: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GCTGCATCC
>PE002200.1 KR 1020220087537-A/45: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
AAGGCGTCT
>PE002192.1 KR 1020220087537-A/29: DOSING REGIMENS FOR TREATING OR PREVENTING C5-ASSOCIATED DISEASES
GATGCATCC
>pdb|8D31|D Chain D, [AG/TC] Self-Assembled 3D DNA Cubic Tensegrity Triangle with 24 bp Arm Length
TCCTGATGT
>pdb|8D31|H Chain H, [AG/TC] Self-Assembled 3D DNA Cubic Tensegrity Triangle with 24 bp Arm Length
TCCTGATGT
>OF490586.1 KR 1020220070324-A/253: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
CACTCGCCA
>OF490536.1 KR 1020220070324-A/203: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
CACTCGCCA
>OF405831.1 KR 1020220035338-A/64: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
TCATCTGTG
>OF405829.1 KR 1020220035338-A/62: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
CTACAGGAA
>OF405791.1 KR 1020220035338-A/24: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
GCAGTGGCG
>OF405774.1 KR 1020220035338-A/7: ENHANCING PRODUCTION OF LENTIVIRAL VECTORS
GTGGAGACT
>OF405767.1 KR 1020220003168-A/35: METHODS AND COMPOSITIONS FOR REDUCING THE IMMUNOGENICITY OF CHIMERIC NOTCH RECEPTORS
GCCGCCACC
>OF405643.1 KR 1020220066225-A/182: COMPOSITIONS AND METHODS FOR SELECTIVE GENE REGULATION
GCGKGGGCG
>OF490629.1 KR 1020220070324-A/296: OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF
CACTCGCCA
>OF404691.1 KR 1020220045109-A/10: CAR-T CELLS TARGETING IL-1RAP AND THEIR USE IN ACUTE MYELOID LEUKEMIA (AML)
TCGGCATCC
>OF404494.1 KR 1020220011727-A/191: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
AAGGCGTCT
>OF404485.1 KR 1020220011727-A/157: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
GTTGCAGCC
>OF404477.1 KR 1020220011727-A/141: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
AAGGTTTCT
>OF404469.1 KR 1020220011727-A/125: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
ACTGCATCC
>OF404461.1 KR 1020220011727-A/109: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
CCTGCATCC
>OF404453.1 KR 1020220011727-A/93: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
ACTACTTCC
>OF404445.1 KR 1020220011727-A/77: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
AAGGCGTCT
>OF404437.1 KR 1020220011727-A/61: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
AAGGCGTCT
>OF404429.1 KR 1020220011727-A/45: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
GCTGCATCC
>OF404421.1 KR 1020220011727-A/29: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
AAGGCGTCT
>OF404413.1 KR 1020220011727-A/13: STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES
GCTGCATCC
>OF404337.1 KR 1020220012333-A/65: COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOCHROMATOSIS
ATAAGTGAA
>OF447071.1 KR 1020220031023-A/11: NOVEL INTRON FRAGMENTS
GTGTCGTGA
>OF403896.1 KR 1020220024160-A/17: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
GTCATACAC
>OF403882.1 KR 1020220024160-A/3: COMPOSITIONS AND METHODS FOR PREPARING AN ALZHEIMER'S DISEASE ANIMAL MODEL USING MICRORNA
TCATACACG
>OF483167.1 KR 1020220076478-A/11: A Method for Identifying, Recognizing or Targeting a DNA Base or Specific DNA Base Sequence by Utilizing a PPR Protein
TCTATCACT
>OF481575.1 KR 1020220053048-A/77: Antisense nucleic acids
TGGAGTTCC
>OF481213.1 KR 1020220063235-A/677: COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
TGGGCCTCT
>OF481159.1 KR 1020220063235-A/327: COMBINATION THERAPY WITH ENTPD2 AND CD73 ANTIBODIES
TGGGCCTCT
>OF480377.1 KR 1020220058631-A/18: N-TERMINAL EXTENSION SEQUENCE FOR EXPRESSION OF RECOMBINANT THERAPEUTIC PEPTIDES
GAGGAAGCG
>OF439120.1 KR 1020220044266-A/3518: CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION
TCGCGAATG
>OF480265.1 KR 1020220049621-A/253: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF480253.1 KR 1020220049621-A/229: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF480241.1 KR 1020220049621-A/205: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GTTGCATCC
>OF480229.1 KR 1020220049621-A/181: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF480217.1 KR 1020220049621-A/157: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF480205.1 KR 1020220049621-A/133: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
AGTGCCTCC
>OF480193.1 KR 1020220049621-A/109: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF480181.1 KR 1020220049621-A/85: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF480169.1 KR 1020220049621-A/61: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGTATCC
>OF480157.1 KR 1020220049621-A/37: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF480145.1 KR 1020220049621-A/13: METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF474774.1 KR 1020220049047-A/253: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF474762.1 KR 1020220049047-A/229: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF474750.1 KR 1020220049047-A/205: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GTTGCATCC
>OF474738.1 KR 1020220049047-A/181: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF474726.1 KR 1020220049047-A/157: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF474714.1 KR 1020220049047-A/133: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
AGTGCCTCC
>OF474702.1 KR 1020220049047-A/109: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF474690.1 KR 1020220049047-A/85: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF474678.1 KR 1020220049047-A/61: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGTATCC
>OF474666.1 KR 1020220049047-A/37: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF474654.1 KR 1020220049047-A/13: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF474568.1 KR 1020220054434-A/227: NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
TTTTWTARG
>OF474567.1 KR 1020220054434-A/226: NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
HDHWDWWNV
>OF474566.1 KR 1020220054434-A/225: NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
ATTGTTGDA
>OF474565.1 KR 1020220054434-A/224: NOVEL CRISPR DNA TARGETING ENZYMES AND SYSTEMS
VHTDKDDDD
>OF387574.1 KR 1020220032516-A/14: FAST-FORWARD SEQUENCING BY SYNTHESIS METHODS
CAGGCCGAC
>OF386222.1 KR 1020220004703-A/125: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCAGCGGC
>OF386195.1 KR 1020220004703-A/98: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCAGCGGC
>OF386168.1 KR 1020220004703-A/71: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCAGCGGC
>OF386155.1 KR 1020220004703-A/58: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCTCCGGA
>OF386134.1 KR 1020220004703-A/37: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCAGCGGC
>OF386106.1 KR 1020220004703-A/9: COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING A CD8 ENGINEERED T CELL THERAPY
GGCAGCGGC
>OF385910.1 KR 1020220027059-A/43: TREATMENT FOR SOD1 ASSOCIATED DISEASE
AACACCCAC
>OF469927.1 KR 1020220063188-A/76: ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
GAGGTCAAG
>OF469915.1 KR 1020220063188-A/61: ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
GAGGTGAAA
>OF469909.1 KR 1020220063188-A/47: ANTIBODY COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS INFECTION
GAGGTTAAA
>OF468999.1 KR 1020220063185-A/141: RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGING
GCTGCATCC
>OF380808.1 KR 1020220004053-A/538: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380768.1 KR 1020220004053-A/458: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380748.1 KR 1020220004053-A/418: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGCGACATC
>OF380728.1 KR 1020220004053-A/378: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380708.1 KR 1020220004053-A/338: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380688.1 KR 1020220004053-A/298: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380628.1 KR 1020220004053-A/178: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380668.1 KR 1020220004053-A/258: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380608.1 KR 1020220004053-A/138: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380648.1 KR 1020220004053-A/218: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380588.1 KR 1020220004053-A/98: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380568.1 KR 1020220004053-A/58: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380548.1 KR 1020220004053-A/18: TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF380343.1 KR 1020220002910-A/24: TRIPLE HELIX TERMINATOR FOR EFFICIENT RNA TRANS-SPLICING
TTTTGCTTT
>OF379429.1 KR 1020220010471-A/29: ELECTROCHEMILUMINESCENT LABELED PROBES FOR USE IN IMMUNOASSAY METHODS, METHODS USING SUCH AND KITS COMPRISING SAME
AAGCGTCTT
>OF463321.1 KR 1020220047826-A/349: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCC
>OF463313.1 KR 1020220047826-A/333: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GGTGCATCC
>OF463305.1 KR 1020220047826-A/317: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCC
>OF463297.1 KR 1020220047826-A/301: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463277.1 KR 1020220047826-A/261: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463269.1 KR 1020220047826-A/245: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCC
>OF463261.1 KR 1020220047826-A/229: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463253.1 KR 1020220047826-A/213: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
AAGGCGTCT
>OF463245.1 KR 1020220047826-A/197: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCC
>OF463237.1 KR 1020220047826-A/181: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
ACTGCATCC
>OF463229.1 KR 1020220047826-A/165: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
ACTGCATCC
>OF463213.1 KR 1020220047826-A/133: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463205.1 KR 1020220047826-A/117: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463201.1 KR 1020220047826-A/109: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463193.1 KR 1020220047826-A/93: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCG
>OF463185.1 KR 1020220047826-A/77: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463177.1 KR 1020220047826-A/61: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GCTGCATCC
>OF463169.1 KR 1020220047826-A/45: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
AAGGCGTCT
>OF463161.1 KR 1020220047826-A/29: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
GATGCATCC
>OF463153.1 KR 1020220047826-A/13: HIGH CONCENTRATION ANTI-C5 FORMULATIONS
AAGGCGTCT
>OF376507.1 KR 1020220063113-A/9: A Salmonella strain and use thereof for the prevention and treatment of cancer
ATGCATAAT
>OF459745.1 KR 1020220044821-A/165: MULTISPECIFIC ANTIGEN-BINDING MOLECULES FOR CELL TARGETING AND USES THEREOF
GCTGCATCC
>OF459632.1 KR 1020220047319-A/191: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GNGCNGCCN
>OF459631.1 KR 1020220047319-A/190: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
CCGAGCNGC
>OF459630.1 KR 1020220047319-A/189: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GCNGCCAAA
>OF459629.1 KR 1020220047319-A/188: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GCNGCCAAA
>OF459628.1 KR 1020220047319-A/187: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGCCA
>OF459606.1 KR 1020220047319-A/165: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GNGCGGCCA
>OF459605.1 KR 1020220047319-A/164: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GANCGGCCA
>OF459604.1 KR 1020220047319-A/163: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGNGGCCA
>OF459603.1 KR 1020220047319-A/162: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCGGCNA
>OF459602.1 KR 1020220047319-A/161: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCGGNCA
>OF459601.1 KR 1020220047319-A/160: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCGNCCA
>OF459600.1 KR 1020220047319-A/159: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGTCA
>OF459599.1 KR 1020220047319-A/158: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGGCA
>OF459598.1 KR 1020220047319-A/157: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGACA
>OF459597.1 KR 1020220047319-A/156: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNTCCA
>OF459596.1 KR 1020220047319-A/155: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNCCCA
>OF459595.1 KR 1020220047319-A/154: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNACCA
>OF459594.1 KR 1020220047319-A/153: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGCCA
>OF459593.1 KR 1020220047319-A/152: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGCCA
>OF459592.1 KR 1020220047319-A/151: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGTNGCCA
>OF459591.1 KR 1020220047319-A/150: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGGNGCCA
>OF459590.1 KR 1020220047319-A/149: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGANGCCA
>OF459526.1 KR 1020220047319-A/85: RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES
GAGCNGCCA
>OF374349.1 KR 1020220040983-A/7: Prime editing-based gene editing composition with improved editing efficiency and use thereof
GGCAAGTTC
>OF374011.1 KR 1020220013339-A/7: A trans-splicing ribozyme specific for rhodopsin transcript and uses thereof
CCCGCCCAA
>OF373923.1 KR 1020220083557-A/4: Mutant ATP-dependent protease and method for producing L-amino acid using the same
ATCAAGCGC
>OF454252.1 KR 1020220035937-A/69: REGULATABLE EXPRESSION SYSTEMS
GAAGAAGAA
>OF454172.1 KR 1020220038397-A/62: CHIMERIC ANTIGEN RECEPTORS WITH MAGE-A4 SPECIFICITY AND USES THEREOF
GATGCATCC
>OF454153.1 KR 1020220038397-A/13: CHIMERIC ANTIGEN RECEPTORS WITH MAGE-A4 SPECIFICITY AND USES THEREOF
GCTGCATCC
>OF495094.1 KR 1020220088446-A/13: ANTI-HEMAGGLUTININ ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF367485.1 KR 1020220057745-A/14: PRIMER SET FOR CLONING OF ENTEROVIRUS
GGGTTAAAA
>OF362887.1 KR 1020220013854-A/12: SPECIFIC HUMANIZED ANTIBODY FOR ANTHRAX PROTECTIVE ANTIGEN AND METHOD FOR MANUFACTURING THEROF
AAGGCCTCC
>OF408616.1 KR 1020220019755-A/61: ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF
GCTGCATCC
>OF408608.1 KR 1020220019755-A/45: ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF
ACTGCATCC
>OF408600.1 KR 1020220019755-A/29: ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF
GCTGCATCC
>OF408592.1 KR 1020220019755-A/13: ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOF
AAGTCGTCT
>OF408071.1 KR 1020220042340-A/7: A trans-splicing ribozyme specific for rhodopsin transcript and uses thereof
CCCGCCCAA
>OF405980.1 KR 1020220004226-A/44: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCAGC
>OF405974.1 KR 1020220004226-A/32: ADMINISTRATION OF AN ANTI-LGR5 MONOCLONAL ANTIBODY
CTGACCTCC
>pdb|7P9Z|I Chain I, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing adenine opposite to lesion)
AGAAAAAAA
>pdb|7P9Z|B Chain B, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing adenine opposite to lesion)
TTTNTTTCT
>pdb|7P8L|I Chain I, Crystal structure of Pyrococcus abyssi 8-oxoguanine DNA glycosylase (PabAGOG) in complex with dsDNA containing cytosine opposite to 8-oxoG
AGAAACAAA
>pdb|7P8L|B Chain B, Crystal structure of Pyrococcus abyssi 8-oxoguanine DNA glycosylase (PabAGOG) in complex with dsDNA containing cytosine opposite to 8-oxoG
TTTNTTTCT
>pdb|7P0W|I Chain I, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing thymine opposite to lesion)
AGAAATAAA
>pdb|7P0W|B Chain B, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing thymine opposite to lesion)
TTTNTTTCT
>pdb|7OY7|I Chain I, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing cytosine opposite to lesion)
AGAAACAAA
>pdb|7OY7|B Chain B, Crystal structure of a trapped Pab-AGOG/double-standed DNA covalent intermediate (DNA containing cytosine opposite to lesion)
TTTNTTTCT
>pdb|7OUE|H Chain H, Crystal structure of a trapped Pab-AGOG/single-standed DNA covalent intermediate
TTTNTTTCT
>pdb|7OUE|F Chain F, Crystal structure of a trapped Pab-AGOG/single-standed DNA covalent intermediate
TTTNTTTCT
>pdb|7OUE|D Chain D, Crystal structure of a trapped Pab-AGOG/single-standed DNA covalent intermediate
TTTNTTTCT
>pdb|7OUE|B Chain B, Crystal structure of a trapped Pab-AGOG/single-standed DNA covalent intermediate
TTTNTTTCT
>PA555871.1 WO 2022196245-A/1: SELECTION MARKER EXPRESSION CASSETTE
ATGGCTTGA
>PA555427.1 JP 2022141049-A/1: METHOD FOR PRODUCING ANTIBODY CONTAINING KAPPA CHAIN
GCCGCCGCC
>pdb|7UXD|B Chain B, Crystal structure of APOBEC3G Catalytic domain complex with ssDNA containing 2'-deoxy Zebularine.
AATCCNAAA
>pdb|7LD5|F Chain F, polynucleotide phosphorylase
AAAAAAAAA
>pdb|7LD5|E Chain E, polynucleotide phosphorylase
AAAAAAAAA
>pdb|7LD5|D Chain D, polynucleotide phosphorylase
AAAAAAAAA
>pdb|7Q4K|D4 Chain D4, Erythromycin-stalled Escherichia coli 70S ribosome with streptococcal MsrDL nascent chain
NTCATGTAA
>pdb|6OST|4 Chain 4, RF2 pre-accommodated state bound Release complex 70S at 24ms
NTCTTCTAA
>pdb|6OSK|4 Chain 4, RF1 accommodated 70S complex at 60 ms
NTCTTCTAA
>pdb|6ORL|4 Chain 4, RF1 pre-accommodated 70S complex at 24 ms
NTCTTCTAA
>pdb|6ORE|4 Chain 4, Release complex 70S
NTCTTCTAA
>pdb|4WT8|A2 Chain A2, Crystal Structure of bactobolin A bound to 70S ribosome-tRNA complex
NAATGTTCA
>pdb|5Y88|x Chain x, Cryo-EM structure of the intron-lariat spliceosome ready for disassembly from S.cerevisiae at 3.5 angstrom
TTTTTTTTT
>pdb|6ENJ|v Chain v, Polyproline-stalled ribosome in the presence of A+P site tRNA and elongation-factor P (EF-P)
NCGCCGCCG
>pdb|6OUO|4 Chain 4, RF2 accommodated state bound 70S complex at long incubation time
NTCTTCTAA
>pdb|6OT3|4 Chain 4, RF2 accommodated state bound Release complex 70S at 24 ms
NTCTTCTAA
>pdb|6OSQ|4 Chain 4, RF1 accommodated state bound Release complex 70S at long incubation time point
NTCTTCTAA
>pdb|7VSJ|B Chain B, Crystal structure of MmIMP3-RRM12 in complex with 9-mer RNA
NACACACAC
>pdb|7QAZ|D Chain D, Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 - Primer Initiation Complex
NAAAATCAA
>pdb|7P9J|D Chain D, Prim-Pol Domain of CRISPR-associated Prim-Pol (CAPP) from Marinitoga sp. 1137 - Primer Initiation Complex
AAAAATCAA
>pdb|5HT2|D Chain D, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with 1-N6-etheno-adenine
NCGAATTCG
>pdb|5HT2|C Chain C, Mouse Tdp2 reaction product (5'-phosphorylated DNA)-Mg2+ complex with 1-N6-etheno-adenine
NCGAATTCG
>pdb|7PAL|Y Chain Y, 70S ribosome with A- and P-site tRNAs in Mycoplasma pneumoniae cells
AATTCTTCA
>pdb|7P6Z|Y Chain Y, Mycoplasma pneumoniae 70S ribosome in untreated cells
TTTTTTTTT
>pdb|7EJC|G Chain G, human RAD51 presynaptic complex
NTTTTTTTT
>pdb|7EJE|E Chain E, human RAD51 post-synaptic complex
NAAAAAAAA
>pdb|7EJE|D Chain D, human RAD51 post-synaptic complex
NTTTTTTTT
>pdb|5XVP|J Chain J, E. fae Cas1-Cas2/prespacer/target ternary complex revealing the fully integrated states
TTCTCCGAG
>pdb|5XVP|I Chain I, E. fae Cas1-Cas2/prespacer/target ternary complex revealing the fully integrated states
NTCTCCGAG
>PA550531.1 WO 2022124282-A/6: PRAME binding molecule
AGGGATAGC
>PA549057.1 WO 2022113799-A/28: ANTISENSE NUCLEIC ACID AND USE THEREOF
AGTGTGGGA
>PA549053.1 WO 2022113799-A/24: ANTISENSE NUCLEIC ACID AND USE THEREOF
TGGAGCTGG
>PA549049.1 WO 2022113799-A/20: ANTISENSE NUCLEIC ACID AND USE THEREOF
TGGAGAGGT
>pdb|7VG8|C Chain C, TYLCV Rep-DNA
TAATATTAC
>PA547033.1 WO 2022102744-A/34: Antibodies directed to spike protein of SARS-CoV-2
CGTGCAAAC
>PA547025.1 WO 2022102744-A/26: Antibodies directed to spike protein of SARS-CoV-2
GGTGCAACC
>PA547017.1 WO 2022102744-A/18: Antibodies directed to spike protein of SARS-CoV-2
TCGGCATCC
>pdb|7UMK|R Chain R, Structure of vesicular stomatitis virus (helical reconstruction, 4.1 A resolution)
NTTTTTTTT
>pdb|7FGT|B Chain B, Discovery of DS15060524; Gene targeting chimera (GeneTAC) for the treatment of Friedreich's Ataxia (FRDA)
CTTCTTCTT
>pdb|7FGT|A Chain A, Discovery of DS15060524; Gene targeting chimera (GeneTAC) for the treatment of Friedreich's Ataxia (FRDA)
AAGAAGAAG
>PA544071.1 WO 2022071492-A/7: Fusion Protein for Suppressing Influenza Virus and Pharmaceutical Composition Comprising Thereof
GGATCCGGG
>PA543329.1 WO 2022075337-A/5: NOVEL ANTI-SUGAR CHAIN ANTIBODIES AND THEIR USES
GAAATATCC
>pdb|7RIQ|R Chain R, RNA polymerase II elongation complex scaffold 1 without polyamide
ATCGAGAGG
>pdb|7RIM|R Chain R, RNA polymerase II elongation complex with hairpin polyamide Py-Im 1, scaffold 1
NTCGAGAGG
>pdb|7KTN|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mg2+ (2160min)
CGGCATACG
>pdb|7KTG|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (960min)
CGGCCTACG
>pdb|7KTF|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mg2+ (180min)
CGGCCTACG
>pdb|7KTE|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mg2+ (90min)
CGGCCTACG
>pdb|7KTA|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
CGGCCTACG
>pdb|7KT9|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (960min)
CGGCATACG
>pdb|7KT8|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 50 mM Mg2+ (180min)
CGGCATACG
>pdb|7KT7|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (60min)
CGGCATACG
>pdb|7KT6|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (960min)
CGGCATACG
>pdb|7KT5|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Product State Ternary Complex, 10 mM Mn2+ (120min)
CGGCATACG
>pdb|7KT4|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Reaction State Ternary Complex, 10 mM Mn2+ (30min)
CGGCATACG
>pdb|7KT3|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
CGGCATACG
>pdb|7KSY|T Chain T, DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (960min)
CGGCCTACG
>pdb|7KSX|T Chain T, DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (30min)
CGGCCTACG
>pdb|7KSW|T Chain T, DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mg2+ (10min)
CGGCCTACG
>pdb|7KSV|T Chain T, DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)
CGGCCTACG
>pdb|7KST|T Chain T, DNA Polymerase Mu, dGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (2min)
CGGCCTACG
>pdb|7JK0|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J1 immobile Holliday junction
NGGAGACTC
>pdb|7JJZ|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J2 immobile Holliday junction
NGAGGACTC
>pdb|7JJY|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J3 immobile Holliday junction with R3 symmetry
NGTCGACTC
>pdb|7JJX|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J5 immobile Holliday junction with R3 symmetry
NGGGGACTC
>pdb|7JJW|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J7 immobile Holliday junction with R3 symmetry
NGGTGACTC
>pdb|7JJ6|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J8 immobile Holliday junction with R3 symmetry
NGACGACTC
>pdb|7JJ5|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J10 immobile Holliday junction with R3 symmetry
NGTCGACTC
>pdb|7JJ4|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J14 immobile Holliday junction with R3 symmetry
NGCCGACTC
>pdb|7JJ3|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J16 immobile Holliday junction with R3 symmetry
NGCCGACTC
>pdb|7JJ2|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J19 immobile Holliday junction with R3 symmetry
NGTCGACTC
>pdb|7JIQ|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J21 immobile Holliday junction with R3 symmetry
NGTGGACTC
>pdb|7JIP|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J22 immobile Holliday junction with R3 symmetry
NGGCGACTC
>pdb|7JIO|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J23 immobile Holliday junction with R3 symmetry
NGACGACTC
>pdb|7JIN|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J24 immobile Holliday junction with R3 symmetry
NGTCGACTC
>pdb|7JIM|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J26 immobile Holliday junction with R3 symmetry
NGACGACTC
>pdb|7JI9|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J30 immobile Holliday junction with R3 symmetry
NGGGGACTC
>pdb|7JI8|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J31 immobile Holliday junction with R3 symmetry
NGGCGACTC
>pdb|7JI7|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J33 immobile Holliday junction with R3 symmetry
NGAGGACTC
>pdb|7JI6|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J34 immobile Holliday junction with R3 symmetry
NGTCGACTC
>pdb|7JI5|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 scramble junction version) containing the J36 immobile Holliday junction with R3 symmetry
NGACGACTC
>pdb|7JHV|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J36 immobile Holliday junction with R3 symmetry
NGACACTCA
>pdb|7JHU|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction with R3 symmetry
CGAGACTCA
>pdb|7JHT|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction with R3 symmetry
NGGCACTCA
>pdb|7JHS|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction with R3 symmetry
NGGGACTCA
>pdb|7JHR|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J4 immobile Holliday junction with R3 symmetry
NGGGACTCA
>pdb|7JHC|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J26 immobile Holliday junction
NGACACTCA
>pdb|7JHB|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J24 immobile Holliday junction
NGTCACTCA
>pdb|7JHA|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J23 immobile Holliday junction
NGACACTCA
>pdb|7JH9|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J22 immobile Holliday junction
NGGCACTCA
>pdb|7JH8|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J20 immobile Holliday junction
NGAGACTCA
>pdb|7JFX|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J16 immobile Holliday junction
NGCCACTCA
>pdb|7JFW|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J10 immobile Holliday junction
NGTCACTCA
>pdb|7JFV|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J7 immobile Holliday junction
NGGTACTCA
>pdb|7JFU|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J5 immobile Holliday junction
NGGGACTCA
>pdb|7JFT|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J2 immobile Holliday junction
NGAGACTCA
>pdb|6XO9|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J33 immobile Holliday junction
NGAGACTCA
>pdb|6XO8|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J31 immobile Holliday junction
NGGCACTCA
>pdb|6XO7|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J30 immobile Holliday junction
NGGGACTCA
>pdb|6XO6|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J28 immobile Holliday junction
NGTCACTCA
>pdb|6XO5|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J8 immobile Holliday junction
NGACACTCA
>pdb|6XNA|B Chain B, Self-assembly of a 3D DNA crystal lattice (4x6 junction version) containing the J1 immobile Holliday junction
NGGAACTCA
>pdb|6X8B|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J6 immobile Holliday junction
TCTGAGTGA
>pdb|6WT1|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J29 immobile Holliday junction
TCTGAGTGC
>pdb|6WT0|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J25 immobile Holliday junction
TCTGAGTGC
>pdb|6WSZ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J24 immobile Holliday junction
TCTGAGTGG
>pdb|6WSY|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J23 immobile Holliday junction
TCTGAGTGG
>pdb|6WSX|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J22 immobile Holliday junction
TCTGAGTGG
>pdb|6WSW|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J21 immobile Holliday junction
TCTGAGTGC
>pdb|6WSV|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J20 immobile Holliday junction
TCTGAGTGC
>pdb|6WSU|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J19 immobile Holliday junction
TCTGAGTGG
>pdb|6WST|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J16 immobile Holliday junction
TCTGAGTGG
>pdb|6WSS|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J15 immobile Holliday junction
TCTGAGTGC
>pdb|6WSR|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J10 immobile Holliday junction
TCTGAGTGG
>pdb|6WSQ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J10 immobile Holliday junction
TCTGAGTGG
>pdb|6WSP|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J9 immobile Holliday junction
TCTGAGTGC
>pdb|6WSO|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J8 immobile Holliday junction
TCTGAGTGG
>pdb|6WSN|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J7 immobile Holliday junction
TCTGAGTGA
>pdb|6WRJ|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J26 immobile Holliday junction
TCTGAGTGA
>pdb|6WRI|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J28 immobile Holliday junction
TCTGAGTGG
>pdb|6WRC|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J31 immobile Holliday junction
TCTGAGTGG
>pdb|6WRB|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J5 immobile Holliday junction
TCTGAGTGC
>pdb|6WRA|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J34 immobile Holliday junction
TCTGAGTGG
>pdb|6WR9|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J32 immobile Holliday junction
TCTGAGTGG
>pdb|6WR7|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J33 immobile Holliday junction
TCTGAGTGC
>pdb|6WR5|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J35 immobile Holliday junction
TCTGAGTGC
>pdb|6WR3|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J36 immobile Holliday junction
TCTGAGTGG
>pdb|6WQG|C Chain C, Self-assembly of a 3D DNA crystal lattice (4x5 duplex version) containing the J3 immobile Holliday junction
TCTGAGTGG
>pdb|4U6M|B Chain B, Crystal structure of DNA/RNA duplex obtained in the presence of Spermine
NTCTTCTTN
>pdb|4U6M|A Chain A, Crystal structure of DNA/RNA duplex obtained in the presence of Spermine
GAAGAAGAG
>pdb|4U6L|B Chain B, Crystal structure of DNA/RNA duplex obtained in the presence of [Co(NH3)6]Cl3 and SrCl2
NTCTTCTTN
>pdb|4U6L|A Chain A, Crystal structure of DNA/RNA duplex obtained in the presence of [Co(NH3)6]Cl3 and SrCl2
GAAGAAGAG
>pdb|4U6K|D Chain D, Crystal structure of DNA/RNA duplex containing 2'-4'-BNA-NC
NNCTTCTNN
>pdb|4U6K|C Chain C, Crystal structure of DNA/RNA duplex containing 2'-4'-BNA-NC
GAAGAAGAG
>pdb|4U6K|B Chain B, Crystal structure of DNA/RNA duplex containing 2'-4'-BNA-NC
NNCTTCTNN
>pdb|4U6K|A Chain A, Crystal structure of DNA/RNA duplex containing 2'-4'-BNA-NC
GAAGAAGAG
>pdb|7TZV|J Chain J, Structure of DriD C-domain bound to 9mer ssDNA
TAGTCTACT
>pdb|7OXS|C Chain C, 1.91 A crystal structure of DNA/2'-O-methyl-RNA heteroduplex
GTCTCCTAG
>pdb|7OXS|A Chain A, 1.91 A crystal structure of DNA/2'-O-methyl-RNA heteroduplex
GTCTCCTAG
>pdb|7OW0|A Chain A, 1.55 A crystal structure of DNA/2'-O-methyl-RNA heteroduplex with overhangs solved by Zn-SAD.
TCTCCTAGG
>OF337866.1 KR 1020210126641-A/13: COMPOSITIONS AND METHODS FOR USING BISPECIFIC ANTIBODIES TO BIND COMPLEMENT AND A TARGET ANTIGEN
GCTGCATCC
>OF334435.1 KR 1020210118862-A/8: HIGH INTENSITY LABELED REACTANT COMPOSITIONS AND METHODS FOR SEQUENCING
CTACCCATA
>OF334434.1 KR 1020210118862-A/7: HIGH INTENSITY LABELED REACTANT COMPOSITIONS AND METHODS FOR SEQUENCING
TATGGGTAG
>OF330257.1 KR 1020210133215-A/20: A METHOD FOR SUPPRESSING NON-SPECIFIC AMPLIFICATION PRODUCTS IN NUCLEIC ACID AMPLIFICATION TECHNOLOGIES
CGGCGTTAT
>OF329738.1 KR 1020210095731-A/253: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF329726.1 KR 1020210095731-A/229: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GATGCATCC
>OF329714.1 KR 1020210095731-A/205: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GTTGCATCC
>OF329702.1 KR 1020210095731-A/181: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF329690.1 KR 1020210095731-A/157: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF329678.1 KR 1020210095731-A/133: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
AGTGCCTCC
>OF329666.1 KR 1020210095731-A/109: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF329654.1 KR 1020210095731-A/85: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
TTGGGTTCT
>OF329642.1 KR 1020210095731-A/61: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGTATCC
>OF329630.1 KR 1020210095731-A/37: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF329618.1 KR 1020210095731-A/13: METHODS FOR TREATING ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R ANTAGONIST
GCTGCATCC
>OF327757.1 KR 1020210106491-A/755: PHARMACEUTICAL COMBINATIONS
TACACCTCC
>OF327756.1 KR 1020210106491-A/754: PHARMACEUTICAL COMBINATIONS
TACACTAGC
>OF327720.1 KR 1020210106491-A/637: PHARMACEUTICAL COMBINATIONS
TGGGCCTCT
>OF327701.1 KR 1020210106491-A/533: PHARMACEUTICAL COMBINATIONS
TGGGCCTCT
>OF324660.1 KR 1020210105914-A/51: NUCLEASE-MEDIATED REPEAT EXPANSION
TCAGTCAGT
>OF321813.1 KR 1020210113597-A/538: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321733.1 KR 1020210113597-A/378: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321773.1 KR 1020210113597-A/458: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321753.1 KR 1020210113597-A/418: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGCGACATC
>OF321713.1 KR 1020210113597-A/338: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321693.1 KR 1020210113597-A/298: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321673.1 KR 1020210113597-A/258: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321653.1 KR 1020210113597-A/218: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321633.1 KR 1020210113597-A/178: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321613.1 KR 1020210113597-A/138: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321593.1 KR 1020210113597-A/98: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321573.1 KR 1020210113597-A/58: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF321553.1 KR 1020210113597-A/18: ACUTE TREATMENT AND RAPID TREATMENT OF HEADACHE USING ANTI-CGRP ANTIBODIES
GGGGACATC
>OF357495.1 KR 1020210143327-A/301: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGCATCC
>OF357479.1 KR 1020210143327-A/269: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>OF357471.1 KR 1020210143327-A/253: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GAAGCATCT
>OF357463.1 KR 1020210143327-A/237: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTTCATCC
>OF357455.1 KR 1020210143327-A/221: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGCGTCC
>OF357447.1 KR 1020210143327-A/205: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GGTGTATCC
>OF357439.1 KR 1020210143327-A/189: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GATGCTTTT
>OF357431.1 KR 1020210143327-A/173: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TTGGGTTCT
>OF357423.1 KR 1020210143327-A/157: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GATGCATCC
>OF357415.1 KR 1020210143327-A/141: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GAGGCGTCC
>OF357407.1 KR 1020210143327-A/125: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTACATCC
>OF357399.1 KR 1020210143327-A/109: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AGTGCATCC
>OF357391.1 KR 1020210143327-A/93: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AAGGCGTCT
>OF357383.1 KR 1020210143327-A/77: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>OF357375.1 KR 1020210143327-A/61: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
GCTGCATCC
>OF357367.1 KR 1020210143327-A/45: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TGGGCATCT
>OF357359.1 KR 1020210143327-A/29: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
AGTGCATCC
>OF357351.1 KR 1020210143327-A/13: HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF
TTGAGTTCT
>OF314922.1 KR 1020210091180-A/10505: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF314914.1 KR 1020210091180-A/10497: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF314906.1 KR 1020210091180-A/10489: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF314860.1 KR 1020210091180-A/10443: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF314801.1 KR 1020210091180-A/10384: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF314788.1 KR 1020210091180-A/10371: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF314776.1 KR 1020210091180-A/10359: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF314764.1 KR 1020210091180-A/10347: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF314752.1 KR 1020210091180-A/10335: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF314740.1 KR 1020210091180-A/10323: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF314727.1 KR 1020210091180-A/10310: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF314714.1 KR 1020210091180-A/10297: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF314701.1 KR 1020210091180-A/10284: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF354973.1 KR 1020210143855-A/67: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
ACTCCGTCG
>OF354970.1 KR 1020210143855-A/64: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GTTCGGAAA
>OF354969.1 KR 1020210143855-A/63: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GACTCCACT
>OF354966.1 KR 1020210143855-A/60: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CGTCGATGC
>OF354965.1 KR 1020210143855-A/59: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TTCGCATTG
>OF354962.1 KR 1020210143855-A/56: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CAGGCTGAA
>OF354961.1 KR 1020210143855-A/55: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TTCCAGCTC
>OF354958.1 KR 1020210143855-A/52: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
ACTCCAACT
>OF354957.1 KR 1020210143855-A/51: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TCCACGGTT
>OF354954.1 KR 1020210143855-A/48: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GACTTCTCT
>OF354953.1 KR 1020210143855-A/47: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TCTCATCCG
>OF354950.1 KR 1020210143855-A/44: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
AAAGTCCCG
>OF354949.1 KR 1020210143855-A/43: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
ATGACGACC
>OF354946.1 KR 1020210143855-A/40: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
ACAACACCT
>OF354945.1 KR 1020210143855-A/39: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GCGTCGTAA
>OF354942.1 KR 1020210143855-A/36: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CGCTACCAG
>OF354941.1 KR 1020210143855-A/35: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
ACGGCTACA
>OF354938.1 KR 1020210143855-A/32: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TCGCAATCT
>OF354937.1 KR 1020210143855-A/31: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CATCAATCG
>OF354914.1 KR 1020210143855-A/8: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CCCCTGGTT
>OF354934.1 KR 1020210143855-A/28: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGAGGCAAG
>OF354933.1 KR 1020210143855-A/27: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TCCCATCAT
>OF354930.1 KR 1020210143855-A/24: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTGGTACT
>OF354929.1 KR 1020210143855-A/23: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
AAGTTGGCG
>OF354926.1 KR 1020210143855-A/20: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTTCCTTC
>OF354925.1 KR 1020210143855-A/19: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
TCCCATCAT
>OF354922.1 KR 1020210143855-A/16: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GGTGGTACT
>OF354921.1 KR 1020210143855-A/15: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CTTTCTCTC
>OF354918.1 KR 1020210143855-A/12: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
GTGGATTCT
>OF354917.1 KR 1020210143855-A/11: MULTIPLEXING REGULATORY ELEMENTS TO IDENTIFY CELL-TYPE SPECIFIC REGULATORY ELEMENTS
CTAACGGTT
>OF314691.1 KR 1020210091180-A/10274: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF314679.1 KR 1020210091180-A/10262: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF314549.1 KR 1020210091180-A/10132: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF314541.1 KR 1020210091180-A/10124: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF314533.1 KR 1020210091180-A/10116: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF314487.1 KR 1020210091180-A/10070: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF314428.1 KR 1020210091180-A/10011: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF314415.1 KR 1020210091180-A/9998: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF314403.1 KR 1020210091180-A/9986: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF314391.1 KR 1020210091180-A/9974: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF314379.1 KR 1020210091180-A/9962: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF314367.1 KR 1020210091180-A/9950: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF314354.1 KR 1020210091180-A/9937: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF314341.1 KR 1020210091180-A/9924: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF314328.1 KR 1020210091180-A/9911: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF314318.1 KR 1020210091180-A/9901: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF314306.1 KR 1020210091180-A/9889: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF314176.1 KR 1020210091180-A/9759: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF314168.1 KR 1020210091180-A/9751: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF314160.1 KR 1020210091180-A/9743: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF314114.1 KR 1020210091180-A/9697: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF314055.1 KR 1020210091180-A/9638: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF314042.1 KR 1020210091180-A/9625: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF314030.1 KR 1020210091180-A/9613: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF314018.1 KR 1020210091180-A/9601: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF314006.1 KR 1020210091180-A/9589: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF313994.1 KR 1020210091180-A/9577: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF313981.1 KR 1020210091180-A/9564: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF313968.1 KR 1020210091180-A/9551: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF313955.1 KR 1020210091180-A/9538: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF313945.1 KR 1020210091180-A/9528: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF313933.1 KR 1020210091180-A/9516: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF313803.1 KR 1020210091180-A/9386: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF313795.1 KR 1020210091180-A/9378: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF313787.1 KR 1020210091180-A/9370: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF313741.1 KR 1020210091180-A/9324: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF313682.1 KR 1020210091180-A/9265: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF313669.1 KR 1020210091180-A/9252: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF313657.1 KR 1020210091180-A/9240: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF313645.1 KR 1020210091180-A/9228: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF313633.1 KR 1020210091180-A/9216: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF313621.1 KR 1020210091180-A/9204: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF313608.1 KR 1020210091180-A/9191: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF313595.1 KR 1020210091180-A/9178: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF313582.1 KR 1020210091180-A/9165: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF313572.1 KR 1020210091180-A/9155: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF313560.1 KR 1020210091180-A/9143: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF313430.1 KR 1020210091180-A/9013: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF313422.1 KR 1020210091180-A/9005: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF313414.1 KR 1020210091180-A/8997: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF313368.1 KR 1020210091180-A/8951: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF313309.1 KR 1020210091180-A/8892: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF313296.1 KR 1020210091180-A/8879: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF313284.1 KR 1020210091180-A/8867: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF313272.1 KR 1020210091180-A/8855: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF313260.1 KR 1020210091180-A/8843: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF313248.1 KR 1020210091180-A/8831: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF313235.1 KR 1020210091180-A/8818: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF313222.1 KR 1020210091180-A/8805: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF313209.1 KR 1020210091180-A/8792: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF313199.1 KR 1020210091180-A/8782: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF313187.1 KR 1020210091180-A/8770: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF313057.1 KR 1020210091180-A/8640: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF313049.1 KR 1020210091180-A/8632: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF313041.1 KR 1020210091180-A/8624: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF312995.1 KR 1020210091180-A/8578: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF312936.1 KR 1020210091180-A/8519: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF312923.1 KR 1020210091180-A/8506: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF312911.1 KR 1020210091180-A/8494: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF312899.1 KR 1020210091180-A/8482: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF312887.1 KR 1020210091180-A/8470: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF312875.1 KR 1020210091180-A/8458: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF312862.1 KR 1020210091180-A/8445: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF312849.1 KR 1020210091180-A/8432: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF312836.1 KR 1020210091180-A/8419: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF312826.1 KR 1020210091180-A/8409: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF312814.1 KR 1020210091180-A/8397: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF352878.1 KR 1020210143230-A/798: METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES
CTGAGCACG
>OF312684.1 KR 1020210091180-A/8267: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF312676.1 KR 1020210091180-A/8259: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF312667.1 KR 1020210091180-A/8250: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF312648.1 KR 1020210091180-A/8231: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF312638.1 KR 1020210091180-A/8221: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF312614.1 KR 1020210091180-A/8197: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF312517.1 KR 1020210091180-A/8100: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF312505.1 KR 1020210091180-A/8088: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF312529.1 KR 1020210091180-A/8112: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF312493.1 KR 1020210091180-A/8076: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF312555.1 KR 1020210091180-A/8138: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF312480.1 KR 1020210091180-A/8063: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF312542.1 KR 1020210091180-A/8125: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF312467.1 KR 1020210091180-A/8050: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF312454.1 KR 1020210091180-A/8037: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF312444.1 KR 1020210091180-A/8027: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF312432.1 KR 1020210091180-A/8015: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF312302.1 KR 1020210091180-A/7885: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF312294.1 KR 1020210091180-A/7877: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF312285.1 KR 1020210091180-A/7868: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF312266.1 KR 1020210091180-A/7849: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF312256.1 KR 1020210091180-A/7839: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF312232.1 KR 1020210091180-A/7815: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF312173.1 KR 1020210091180-A/7756: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF312160.1 KR 1020210091180-A/7743: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF312147.1 KR 1020210091180-A/7730: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF312135.1 KR 1020210091180-A/7718: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF312123.1 KR 1020210091180-A/7706: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF312111.1 KR 1020210091180-A/7694: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF312098.1 KR 1020210091180-A/7681: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF312085.1 KR 1020210091180-A/7668: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF312072.1 KR 1020210091180-A/7655: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF312062.1 KR 1020210091180-A/7645: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF312050.1 KR 1020210091180-A/7633: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF311920.1 KR 1020210091180-A/7503: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF311912.1 KR 1020210091180-A/7495: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF311903.1 KR 1020210091180-A/7486: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF311884.1 KR 1020210091180-A/7467: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF311874.1 KR 1020210091180-A/7457: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF311850.1 KR 1020210091180-A/7433: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF311791.1 KR 1020210091180-A/7374: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF311778.1 KR 1020210091180-A/7361: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF311765.1 KR 1020210091180-A/7348: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF311753.1 KR 1020210091180-A/7336: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF311741.1 KR 1020210091180-A/7324: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF311729.1 KR 1020210091180-A/7312: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF311716.1 KR 1020210091180-A/7299: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF311703.1 KR 1020210091180-A/7286: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF311690.1 KR 1020210091180-A/7273: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF311680.1 KR 1020210091180-A/7263: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF311668.1 KR 1020210091180-A/7251: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF311538.1 KR 1020210091180-A/7121: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF311530.1 KR 1020210091180-A/7113: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF311521.1 KR 1020210091180-A/7104: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF311502.1 KR 1020210091180-A/7085: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF311492.1 KR 1020210091180-A/7075: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF311468.1 KR 1020210091180-A/7051: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF311308.1 KR 1020210091180-A/6891: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF311298.1 KR 1020210091180-A/6881: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF311286.1 KR 1020210091180-A/6869: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF311409.1 KR 1020210091180-A/6992: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF311396.1 KR 1020210091180-A/6979: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF311383.1 KR 1020210091180-A/6966: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF311371.1 KR 1020210091180-A/6954: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF311359.1 KR 1020210091180-A/6942: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF311347.1 KR 1020210091180-A/6930: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF311334.1 KR 1020210091180-A/6917: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF311321.1 KR 1020210091180-A/6904: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF311156.1 KR 1020210091180-A/6739: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF311148.1 KR 1020210091180-A/6731: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF311139.1 KR 1020210091180-A/6722: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF311120.1 KR 1020210091180-A/6703: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF311110.1 KR 1020210091180-A/6693: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF311086.1 KR 1020210091180-A/6669: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF311027.1 KR 1020210091180-A/6610: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF311014.1 KR 1020210091180-A/6597: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF311001.1 KR 1020210091180-A/6584: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF310989.1 KR 1020210091180-A/6572: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF310977.1 KR 1020210091180-A/6560: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF310965.1 KR 1020210091180-A/6548: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF310952.1 KR 1020210091180-A/6535: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF310939.1 KR 1020210091180-A/6522: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF310926.1 KR 1020210091180-A/6509: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF310916.1 KR 1020210091180-A/6499: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF310904.1 KR 1020210091180-A/6487: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF310774.1 KR 1020210091180-A/6357: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF310766.1 KR 1020210091180-A/6349: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF310757.1 KR 1020210091180-A/6340: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF310738.1 KR 1020210091180-A/6321: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF310728.1 KR 1020210091180-A/6311: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF310704.1 KR 1020210091180-A/6287: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF310645.1 KR 1020210091180-A/6228: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF310632.1 KR 1020210091180-A/6215: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF310619.1 KR 1020210091180-A/6202: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF310607.1 KR 1020210091180-A/6190: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF310595.1 KR 1020210091180-A/6178: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF310583.1 KR 1020210091180-A/6166: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF310570.1 KR 1020210091180-A/6153: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF310557.1 KR 1020210091180-A/6140: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF310544.1 KR 1020210091180-A/6127: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF310534.1 KR 1020210091180-A/6117: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF310522.1 KR 1020210091180-A/6105: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF310392.1 KR 1020210091180-A/5975: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF310384.1 KR 1020210091180-A/5967: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF310376.1 KR 1020210091180-A/5959: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF310341.1 KR 1020210091180-A/5924: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF310328.1 KR 1020210091180-A/5911: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF310269.1 KR 1020210091180-A/5852: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF310256.1 KR 1020210091180-A/5839: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF310244.1 KR 1020210091180-A/5827: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF310232.1 KR 1020210091180-A/5815: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF310220.1 KR 1020210091180-A/5803: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF310208.1 KR 1020210091180-A/5791: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF310195.1 KR 1020210091180-A/5778: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF310182.1 KR 1020210091180-A/5765: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF310169.1 KR 1020210091180-A/5752: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF310159.1 KR 1020210091180-A/5742: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF310017.1 KR 1020210091180-A/5600: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF310009.1 KR 1020210091180-A/5592: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF310001.1 KR 1020210091180-A/5584: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF309966.1 KR 1020210091180-A/5549: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF309953.1 KR 1020210091180-A/5536: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF310147.1 KR 1020210091180-A/5730: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF309894.1 KR 1020210091180-A/5477: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF309881.1 KR 1020210091180-A/5464: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF309869.1 KR 1020210091180-A/5452: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF309857.1 KR 1020210091180-A/5440: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF309845.1 KR 1020210091180-A/5428: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF309833.1 KR 1020210091180-A/5416: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF309820.1 KR 1020210091180-A/5403: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF309807.1 KR 1020210091180-A/5390: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF309794.1 KR 1020210091180-A/5377: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF309784.1 KR 1020210091180-A/5367: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF309772.1 KR 1020210091180-A/5355: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF309642.1 KR 1020210091180-A/5225: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF309634.1 KR 1020210091180-A/5217: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF309626.1 KR 1020210091180-A/5209: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF309519.1 KR 1020210091180-A/5102: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF309591.1 KR 1020210091180-A/5174: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF309506.1 KR 1020210091180-A/5089: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF309578.1 KR 1020210091180-A/5161: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF309494.1 KR 1020210091180-A/5077: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF309482.1 KR 1020210091180-A/5065: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF309470.1 KR 1020210091180-A/5053: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF309458.1 KR 1020210091180-A/5041: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF309445.1 KR 1020210091180-A/5028: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF309432.1 KR 1020210091180-A/5015: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF309419.1 KR 1020210091180-A/5002: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF309409.1 KR 1020210091180-A/4992: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF309397.1 KR 1020210091180-A/4980: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF309267.1 KR 1020210091180-A/4850: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF309259.1 KR 1020210091180-A/4842: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF309251.1 KR 1020210091180-A/4834: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF309216.1 KR 1020210091180-A/4799: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF309203.1 KR 1020210091180-A/4786: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF309119.1 KR 1020210091180-A/4702: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF309107.1 KR 1020210091180-A/4690: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF309095.1 KR 1020210091180-A/4678: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF309083.1 KR 1020210091180-A/4666: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF309070.1 KR 1020210091180-A/4653: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF309057.1 KR 1020210091180-A/4640: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF309044.1 KR 1020210091180-A/4627: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF309034.1 KR 1020210091180-A/4617: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF309022.1 KR 1020210091180-A/4605: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF309144.1 KR 1020210091180-A/4727: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF309131.1 KR 1020210091180-A/4714: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF308892.1 KR 1020210091180-A/4475: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF308884.1 KR 1020210091180-A/4467: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF308876.1 KR 1020210091180-A/4459: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF308841.1 KR 1020210091180-A/4424: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF308828.1 KR 1020210091180-A/4411: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF308769.1 KR 1020210091180-A/4352: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF308756.1 KR 1020210091180-A/4339: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF308744.1 KR 1020210091180-A/4327: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF308732.1 KR 1020210091180-A/4315: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF308720.1 KR 1020210091180-A/4303: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF308708.1 KR 1020210091180-A/4291: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF308695.1 KR 1020210091180-A/4278: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF308682.1 KR 1020210091180-A/4265: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF308669.1 KR 1020210091180-A/4252: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF308659.1 KR 1020210091180-A/4242: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF308647.1 KR 1020210091180-A/4230: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF308517.1 KR 1020210091180-A/4100: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF308509.1 KR 1020210091180-A/4092: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF308501.1 KR 1020210091180-A/4084: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF308466.1 KR 1020210091180-A/4049: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF308453.1 KR 1020210091180-A/4036: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF308394.1 KR 1020210091180-A/3977: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF308381.1 KR 1020210091180-A/3964: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF308369.1 KR 1020210091180-A/3952: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF308357.1 KR 1020210091180-A/3940: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF308345.1 KR 1020210091180-A/3928: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF308333.1 KR 1020210091180-A/3916: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF348859.1 KR 1020210142659-A/19: EGFR x CD28 MULTISPECIFIC ANTIBODIES
GGGGCAAGT
>OF308320.1 KR 1020210091180-A/3903: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF308307.1 KR 1020210091180-A/3890: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF308294.1 KR 1020210091180-A/3877: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF308284.1 KR 1020210091180-A/3867: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF308272.1 KR 1020210091180-A/3855: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF308142.1 KR 1020210091180-A/3725: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF308134.1 KR 1020210091180-A/3717: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF307935.1 KR 1020210091180-A/3518: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF307922.1 KR 1020210091180-A/3505: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF307909.1 KR 1020210091180-A/3492: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF307899.1 KR 1020210091180-A/3482: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF307887.1 KR 1020210091180-A/3470: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF308125.1 KR 1020210091180-A/3708: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF308106.1 KR 1020210091180-A/3689: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF308095.1 KR 1020210091180-A/3678: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF308082.1 KR 1020210091180-A/3665: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF308069.1 KR 1020210091180-A/3652: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF307757.1 KR 1020210091180-A/3340: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF307749.1 KR 1020210091180-A/3332: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF307740.1 KR 1020210091180-A/3323: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF308010.1 KR 1020210091180-A/3593: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF307997.1 KR 1020210091180-A/3580: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF307984.1 KR 1020210091180-A/3567: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF307972.1 KR 1020210091180-A/3555: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF307960.1 KR 1020210091180-A/3543: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF307948.1 KR 1020210091180-A/3531: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF307721.1 KR 1020210091180-A/3304: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF307710.1 KR 1020210091180-A/3293: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF307697.1 KR 1020210091180-A/3280: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF307684.1 KR 1020210091180-A/3267: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF307625.1 KR 1020210091180-A/3208: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF307612.1 KR 1020210091180-A/3195: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF307599.1 KR 1020210091180-A/3182: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF307587.1 KR 1020210091180-A/3170: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF307575.1 KR 1020210091180-A/3158: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF307563.1 KR 1020210091180-A/3146: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF307550.1 KR 1020210091180-A/3133: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF307537.1 KR 1020210091180-A/3120: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF307524.1 KR 1020210091180-A/3107: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF307514.1 KR 1020210091180-A/3097: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF307502.1 KR 1020210091180-A/3085: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF307336.1 KR 1020210091180-A/2919: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF307325.1 KR 1020210091180-A/2908: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF307312.1 KR 1020210091180-A/2895: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF307299.1 KR 1020210091180-A/2882: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF307372.1 KR 1020210091180-A/2955: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF307364.1 KR 1020210091180-A/2947: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF307355.1 KR 1020210091180-A/2938: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF307240.1 KR 1020210091180-A/2823: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF307227.1 KR 1020210091180-A/2810: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF307214.1 KR 1020210091180-A/2797: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF307202.1 KR 1020210091180-A/2785: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF307190.1 KR 1020210091180-A/2773: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF307178.1 KR 1020210091180-A/2761: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF307165.1 KR 1020210091180-A/2748: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF307152.1 KR 1020210091180-A/2735: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF307139.1 KR 1020210091180-A/2722: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF307129.1 KR 1020210091180-A/2712: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF307117.1 KR 1020210091180-A/2700: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF306987.1 KR 1020210091180-A/2570: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF306979.1 KR 1020210091180-A/2562: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF306970.1 KR 1020210091180-A/2553: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF306951.1 KR 1020210091180-A/2534: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF306940.1 KR 1020210091180-A/2523: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF306927.1 KR 1020210091180-A/2510: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF306914.1 KR 1020210091180-A/2497: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF306855.1 KR 1020210091180-A/2438: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF306842.1 KR 1020210091180-A/2425: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF306732.1 KR 1020210091180-A/2315: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF306829.1 KR 1020210091180-A/2412: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF306817.1 KR 1020210091180-A/2400: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF306805.1 KR 1020210091180-A/2388: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF306793.1 KR 1020210091180-A/2376: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF306780.1 KR 1020210091180-A/2363: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF306767.1 KR 1020210091180-A/2350: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF306754.1 KR 1020210091180-A/2337: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF306744.1 KR 1020210091180-A/2327: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF306542.1 KR 1020210091180-A/2125: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF306529.1 KR 1020210091180-A/2112: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF306470.1 KR 1020210091180-A/2053: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF306457.1 KR 1020210091180-A/2040: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF306444.1 KR 1020210091180-A/2027: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF306432.1 KR 1020210091180-A/2015: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF306420.1 KR 1020210091180-A/2003: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF306408.1 KR 1020210091180-A/1991: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF306395.1 KR 1020210091180-A/1978: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF306602.1 KR 1020210091180-A/2185: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF306594.1 KR 1020210091180-A/2177: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF306382.1 KR 1020210091180-A/1965: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF306585.1 KR 1020210091180-A/2168: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF306369.1 KR 1020210091180-A/1952: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF306359.1 KR 1020210091180-A/1942: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF306566.1 KR 1020210091180-A/2149: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF306555.1 KR 1020210091180-A/2138: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF306347.1 KR 1020210091180-A/1930: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF306217.1 KR 1020210091180-A/1800: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF306209.1 KR 1020210091180-A/1792: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF306200.1 KR 1020210091180-A/1783: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF306181.1 KR 1020210091180-A/1764: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF306170.1 KR 1020210091180-A/1753: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF306157.1 KR 1020210091180-A/1740: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF306144.1 KR 1020210091180-A/1727: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF306085.1 KR 1020210091180-A/1668: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF306072.1 KR 1020210091180-A/1655: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF306059.1 KR 1020210091180-A/1642: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF306047.1 KR 1020210091180-A/1630: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF306035.1 KR 1020210091180-A/1618: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF306023.1 KR 1020210091180-A/1606: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF306010.1 KR 1020210091180-A/1593: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF305997.1 KR 1020210091180-A/1580: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF305984.1 KR 1020210091180-A/1567: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF305974.1 KR 1020210091180-A/1557: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF305962.1 KR 1020210091180-A/1545: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF305832.1 KR 1020210091180-A/1415: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF305824.1 KR 1020210091180-A/1407: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF305816.1 KR 1020210091180-A/1399: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF305770.1 KR 1020210091180-A/1353: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF305711.1 KR 1020210091180-A/1294: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF305698.1 KR 1020210091180-A/1281: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF305686.1 KR 1020210091180-A/1269: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF305674.1 KR 1020210091180-A/1257: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF305662.1 KR 1020210091180-A/1245: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF305650.1 KR 1020210091180-A/1233: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF305637.1 KR 1020210091180-A/1220: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF305459.1 KR 1020210091180-A/1042: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF305451.1 KR 1020210091180-A/1034: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF305442.1 KR 1020210091180-A/1025: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF305423.1 KR 1020210091180-A/1006: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF305413.1 KR 1020210091180-A/996: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF305624.1 KR 1020210091180-A/1207: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF305611.1 KR 1020210091180-A/1194: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF305389.1 KR 1020210091180-A/972: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF305601.1 KR 1020210091180-A/1184: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF305589.1 KR 1020210091180-A/1172: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF305330.1 KR 1020210091180-A/913: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF305317.1 KR 1020210091180-A/900: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF305304.1 KR 1020210091180-A/887: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF305292.1 KR 1020210091180-A/875: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF305280.1 KR 1020210091180-A/863: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF305268.1 KR 1020210091180-A/851: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF305255.1 KR 1020210091180-A/838: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF305242.1 KR 1020210091180-A/825: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF305229.1 KR 1020210091180-A/812: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF305219.1 KR 1020210091180-A/802: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF305207.1 KR 1020210091180-A/790: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF305077.1 KR 1020210091180-A/660: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF305069.1 KR 1020210091180-A/652: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF305061.1 KR 1020210091180-A/644: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF305026.1 KR 1020210091180-A/609: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF305013.1 KR 1020210091180-A/596: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF304941.1 KR 1020210091180-A/524: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF304929.1 KR 1020210091180-A/512: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF304954.1 KR 1020210091180-A/537: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF304917.1 KR 1020210091180-A/500: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF304905.1 KR 1020210091180-A/488: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF304893.1 KR 1020210091180-A/476: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF304880.1 KR 1020210091180-A/463: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF304867.1 KR 1020210091180-A/450: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF304854.1 KR 1020210091180-A/437: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF304844.1 KR 1020210091180-A/427: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF304832.1 KR 1020210091180-A/415: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF304702.1 KR 1020210091180-A/285: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGATGGCAT
>OF304694.1 KR 1020210091180-A/277: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGATGGCA
>OF304685.1 KR 1020210091180-A/268: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GAAGATGGC
>OF304666.1 KR 1020210091180-A/249: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGGAAGATG
>OF304655.1 KR 1020210091180-A/238: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGGAAGAT
>OF304642.1 KR 1020210091180-A/225: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CAAGGAAGA
>OF304629.1 KR 1020210091180-A/212: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCAAGGAAG
>OF304570.1 KR 1020210091180-A/153: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCGGTAAGT
>OF304557.1 KR 1020210091180-A/140: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CGGTAAGTT
>OF304544.1 KR 1020210091180-A/127: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GGTAAGTTC
>OF304532.1 KR 1020210091180-A/115: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTAAGTTCT
>OF304520.1 KR 1020210091180-A/103: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TAAGTTCTG
>OF304508.1 KR 1020210091180-A/91: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AAGTTCTGT
>OF304495.1 KR 1020210091180-A/78: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
AGTTCTGTC
>OF304482.1 KR 1020210091180-A/65: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
GTTCTGTCC
>OF304469.1 KR 1020210091180-A/52: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
CTGTCCAAG
>OF304459.1 KR 1020210091180-A/42: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TCTGTCCAA
>OF304447.1 KR 1020210091180-A/30: BISPECIFIC ANTISENSE OLIGONUCLEOTIDES FOR DYSTROPHIN EXON SKIPPING
TTCTGTCCA
>OF304004.1 KR 1020210093856-A/130: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GATGCATCC
>OF303994.1 KR 1020210093856-A/110: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
ACTGCATCC
>OF303984.1 KR 1020210093856-A/91: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GCTGCTTCC
>OF303974.1 KR 1020210093856-A/71: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF303961.1 KR 1020210093856-A/45: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF303953.1 KR 1020210093856-A/29: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF303945.1 KR 1020210093856-A/13: ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF299740.1 KR 1020210131243-A/17: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GTGTATGAC
>OF299727.1 KR 1020210131243-A/4: USE OF DOWNREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
CGTGTATGA
>OF299696.1 KR 1020210131242-A/17: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
GTGTATGAC
>OF299683.1 KR 1020210131242-A/4: USE OF UPREGULATED MIRNA FOR DIAGNOSIS AND TREATMENT
CGTGTATGA
>OF298191.1 KR 1020210154422-A/15: ANTI SPYCAS9 ANTIBODY AND USE THEREOF
TCGACATCC
>OF300667.1 KR 1020210112295-A/52: CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
AAAGTGAGC
>OF300661.1 KR 1020210112295-A/46: CHIMERIC ANTIGEN RECEPTORS AGAINST MULTIPLE HLA-G ISOFORMS
TTCACCTCC
>OF298543.1 KR 1020210119256-A/6: Novel guide RNA and method for diagnosing Coronavirus disease 2019
TTTTATTTT
>OF300429.1 KR 1020210132628-A/6: Novel guide RNA and method for diagnosing Coronavirus disease 2019
TTTTATTTT
>pdb|7KTM|T Chain T, DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (30min)
CGGCCTACG
>pdb|7KTL|T Chain T, DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (90min)
CGGCCTACG
>pdb|7KTK|T Chain T, DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Ground State Ternary Complex, 50 mM Mg2+ (90min)
CGGCCTACG
>pdb|7KTJ|T Chain T, DNA Polymerase Mu (K438D), 8-oxodGTP:Ct Pre-Catalytic Ground State Ternary Complex, 20 mM Ca2+ (120min)
CGGCCTACG
>pdb|7KTI|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 20 uM Mn2+ (120min)
CGGCCTACG
>pdb|7KTH|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mg2+ (2160min)
CGGCCTACG
>pdb|7KTD|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (960min)
CGGCCTACG
>pdb|7KTC|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (120min)
CGGCCTACG
>pdb|7KTB|T Chain T, DNA Polymerase Mu, 8-oxodGTP:Ct Reaction State Ternary Complex, 10 mM Mn2+ (40min)
CGGCCTACG
>pdb|7KSS|T Chain T, DNA Polymerase Mu, dGTP:Ct Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (20min)
CGGCCTACG
>pdb|7U7L|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s with flipped-out product
AGCGTCATG
>pdb|7U7K|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 600s
AGCGTCATG
>pdb|7U7J|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 300s
AGCGTCATG
>pdb|7U7I|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 180s
AGCGTCATG
>pdb|7U7G|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 120s
AGCGTCATG
>pdb|7U7F|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 10.0 mM Mn2+ for 90s
AGCGTCATG
>pdb|7U7C|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 300s
AGCGTCATG
>pdb|7U7B|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 250s
AGCGTCATG
>pdb|7U7A|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 200s
AGCGTCATG
>pdb|7U79|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 1.0 mM Mg2+ for 140s
AGCGTCATG
>pdb|7U76|P Chain P, Human DNA polymerase eta-DNA ternary mismatch complex:reaction with 0.5 mM Mn2+ for 1800s then with 10 mM Mn2+ for 300s
AGCGTCATG
>pdb|2KKK|D Chain D, An i-motif structure with intercalated T T pairs
NCTCTCTCC
>pdb|2KKK|C Chain C, An i-motif structure with intercalated T T pairs
NCTCTCTCC
>pdb|2KKK|B Chain B, An i-motif structure with intercalated T T pairs
NCTCTCTCC
>pdb|2KKK|A Chain A, An i-motif structure with intercalated T T pairs
NCTCTCTCC
>pdb|2K41|A Chain A, NMR structure of uridine bulged RNA duplex
GTCGTGCTG
>pdb|2AWV|B Chain B, NMR Structural Analysis of the dimer of 5MCCTCATCC
NCTCACTCC
>pdb|2AWV|A Chain A, NMR Structural Analysis of the dimer of 5MCCTCATCC
NCTCACTCC
>pdb|7NBP|B Chain B, Solution structure of DNA duplex containing a 7,8-dihydro-8-oxo-1,N6-ethenoadenine base modification that induces exclusively A-_T transversions in Escherichia coli
CATGAGTAC
>pdb|7NBP|A Chain A, Solution structure of DNA duplex containing a 7,8-dihydro-8-oxo-1,N6-ethenoadenine base modification that induces exclusively A-_T transversions in Escherichia coli
GTACNCATG
>pdb|5H1C|E Chain E, Human RAD51 post-synaptic complexes
NAAAAAAAA
>pdb|5H1C|D Chain D, Human RAD51 post-synaptic complexes
NTTTTTTTT
>pdb|5H1B|D Chain D, Human RAD51 presynaptic complex
NTTTTTTTT
>pdb|4YFU|E Chain E, Crystal structure of open Bacillus fragment DNA polymerase bound to DNA and dTTP
CATGATGCN
>pdb|4YFU|B Chain B, Crystal structure of open Bacillus fragment DNA polymerase bound to DNA and dTTP
CATGATGCN
>pdb|2K3Z|A Chain A, NMR structure of adenosine bulged RNA duplex with C:G-A triple
GTCGAGCTG
>pdb|2O81|B Chain B, The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
GCNGANGCA
>pdb|2O81|A Chain A, The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
GCNGANGCA
>pdb|5L1I|P Chain P, Crystal Structure of Human DNA Polymerase Eta Inserting dCTP Opposite O6-Methyl-2'-deoxyguanosine
AGCGTCATC
>pdb|2KY2|B Chain B, The Structure of RNA Internal Loops with Tandem AG Pairs: 5'UAGG/3'GGAU
GGTAGGCCA
>pdb|2KY2|A Chain A, The Structure of RNA Internal Loops with Tandem AG Pairs: 5'UAGG/3'GGAU
GGTAGGCCA
>pdb|2H49|B Chain B, The NMR Structure of an Internal Loop from 23S Ribosomal RNA of Deinococcus radiodurans Differs from the Structure in the Crystal of the Ribosomal Subunit
GTCGAAGCC
>pdb|2H49|A Chain A, The NMR Structure of an Internal Loop from 23S Ribosomal RNA of Deinococcus radiodurans Differs from the Structure in the Crystal of the Ribosomal Subunit
GGCTAAGAC
>pdb|2O83|B Chain B, The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
GGNGANCCA
>pdb|2O83|A Chain A, The Structure of Tandem GA RNA Pairs When Flanking Pairs are isoG-isoC Pairs
GGNGANCCA
>pdb|2IRO|B Chain B, The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
NCGGATGCT
>pdb|2IRO|A Chain A, The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
NCGGATGCT
>pdb|2IRN|B Chain B, The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
NCTGAGGCT
>pdb|2IRN|A Chain A, The NMR Structures of (rGCUGAGGCU)2 and (rGCGGAUGCU)2
NCTGAGGCT
>pdb|7EJ7|E Chain E, Yeast Dmc1 post-synaptic complex
NAAAAAAAA
>pdb|7EJ7|D Chain D, Yeast Dmc1 post-synaptic complex
NTTTTTTTT
>pdb|7EJ6|D Chain D, Yeast Dmc1 presynaptic complex
NTTTTTTTT
>pdb|7RZZ|B Chain B, Crystal structure of FBF-2 in complex with LST-1 site A peptide and compact FBE RNA
CTGTGAATG
>PA369546.1 JP 2021532057-A/47: A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN TREATING A METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA
GGTGCATCC
>PA369506.1 JP 2021532057-A/7: A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN TREATING A METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA
GCTGCATCC
>PA368662.1 WO 2021251466-A/6: Method of efficiently producing induced pluripotent stem cells
GGGCGGGGC
>pdb|7ORO|P Chain P, La Crosse virus polymerase at replication early-elongation stage
NGTAGTGTA
>pdb|7QE0|E Chain E, 80S-bound human SKI complex in the open state
NTTTTTTTT
>pdb|1RGO|D Chain D, Structural Basis for Recognition of the mRNA Class II AU-Rich Element by the Tandem Zinc Finger Domain of TIS11d
TTATTTATT
>pdb|1NAO|B Chain B, SOLUTION STRUCTURE OF AN RNA 2'-O-METHYLATED RNA DUPLEX CONTAINING AN RNA/DNA HYBRID SEGMENT AT THE CENTER, NMR, MINIMIZED AVERAGE STRUCTURE
NNNATCTNN
>pdb|1DK9|B Chain B, SOLUTION STRUCTURE ANALYSIS OF THE DNA DUPLEX D(CATGAGTAC)D(GTACTCATG)
GTACTCATG
>pdb|1C2Q|B Chain B, SOLUTION STRUCTURE OF A DNA.RNA HYBRID CONTAINING AN ALPHAT-ANOMERIC THYMIDINE AND POLARITY REVERSALS
GAGCACCAT
>pdb|1DK6|B Chain B, NMR structure analysis of the DNA nine base pair duplex D(CATGAGTAC) D(GTAC(NP3)CATG)
GTACNCATG
>pdb|1NYD|D Chain D, Solution structure of DNA quadruplex GCGGTGGAT
GCGGTGGAT
>pdb|1NYD|C Chain C, Solution structure of DNA quadruplex GCGGTGGAT
GCGGTGGAT
>pdb|1NYD|B Chain B, Solution structure of DNA quadruplex GCGGTGGAT
GCGGTGGAT
>pdb|1NYD|A Chain A, Solution structure of DNA quadruplex GCGGTGGAT
GCGGTGGAT
>pdb|1OSR|A Chain A, Structural study of dna duplex containaing a n-(2-deoxy-beta-erytho-pentofuranosyl) formamide frameshift by nmr and restrained molecular dynamics
AGGACCACG
>pdb|1NTQ|A Chain A, 5'(dCCUCCUU)3':3'(rAGGAGGAAA)5'
AAAGGAGGA
>pdb|1N53|B Chain B, SOLUTION STRUCTURE OF B. SUBTILIS T BOX ANTITERMINATOR RNA
GCGTCCCTC
>pdb|1NP5|B Chain B, (GAC)3 parallel duplex
GACGACGAC
>pdb|1NP5|A Chain A, (GAC)3 parallel duplex
GACGACGAC
>pdb|1MV6|B Chain B, The tandem, Sheared PP Pairs in 5'(rGGCPPGCCU)2
GGCNNGCCT
>pdb|1MV6|A Chain A, The tandem, Sheared PP Pairs in 5'(rGGCPPGCCU)2
GGCNNGCCT
>pdb|1MV2|B Chain B, The tandem, Face-to-Face AP Pairs in 5'(rGGCAPGCCU)2
GGCANGCCT
>pdb|1MV2|A Chain A, The tandem, Face-to-Face AP Pairs in 5'(rGGCAPGCCU)2
GGCANGCCT
>pdb|1MV1|B Chain B, The Tandem, Sheared PA Pairs in 5'(rGGCPAGCCU)2
GGCNAGCCT
>pdb|1MV1|A Chain A, The Tandem, Sheared PA Pairs in 5'(rGGCPAGCCU)2
GGCNAGCCT
>pdb|1MUV|B Chain B, Sheared A(anti)-A(anti) Base Pairs in a Destabilizing 2x2 Internal Loop: The NMR Structure of 5'(rGGCAAGCCU)2
GGCAAGCCT
>pdb|1MUV|A Chain A, Sheared A(anti)-A(anti) Base Pairs in a Destabilizing 2x2 Internal Loop: The NMR Structure of 5'(rGGCAAGCCU)2
GGCAAGCCT
>pdb|1LPW|A Chain A, Solution structure of the yeast spliceosomal U2 snRNA-intron branch site helix featuring a conserved pseudouridine
GGTGNAGTA
>pdb|1LMV|A Chain A, Solution structure of the unmodified U2 snRNA-intron branch site helix from S. cerevisiae
GGTGTAGTA
>pdb|1FZS|A Chain A, DNA WITH PYRENE PAIRED AT ABASIC SITE
CACAAACAN
>pdb|1F3S|B Chain B, Solution Structure of DNA Sequence GGGTTCAGG Forms GGGG Tetrade and G(C-A) Triad.
GGGTTCAGG
>pdb|1F3S|A Chain A, Solution Structure of DNA Sequence GGGTTCAGG Forms GGGG Tetrade and G(C-A) Triad.
GGGTTCAGG
>pdb|1C4L|B Chain B, SOLUTION STRUCTURE OF AN RNA DUPLEX INCLUDING A C-U BASE-PAIR
CCTGCGTCG
>pdb|1C4L|A Chain A, SOLUTION STRUCTURE OF AN RNA DUPLEX INCLUDING A C-U BASE-PAIR
CGACTCAGG
>pdb|1DK6|A Chain A, NMR structure analysis of the DNA nine base pair duplex D(CATGAGTAC) D(GTAC(NP3)CATG)
CATGAGTAC
>pdb|1DK9|A Chain A, SOLUTION STRUCTURE ANALYSIS OF THE DNA DUPLEX D(CATGAGTAC)D(GTACTCATG)
CATGAGTAC
>pdb|1C2Q|A Chain A, SOLUTION STRUCTURE OF A DNA.RNA HYBRID CONTAINING AN ALPHAT-ANOMERIC THYMIDINE AND POLARITY REVERSALS
ATGGNGCTC
>pdb|1AX7|B Chain B, SOLUTION STRUCTURE OF THE [AF]-C8-DG ADDUCT POSITIONED AT A TEMPLATE-PRIMER JUNCTION, NMR, 6 STRUCTURES
GGATGGTAG
>pdb|1OKA|A Chain A, RNA/DNA CHIMERA, NMR
TCATTTGGG
>pdb|1NAO|A Chain A, SOLUTION STRUCTURE OF AN RNA 2'-O-METHYLATED RNA DUPLEX CONTAINING AN RNA/DNA HYBRID SEGMENT AT THE CENTER, NMR, MINIMIZED AVERAGE STRUCTURE
GGAGATGAC
>pdb|1DRN|B Chain B, NMR SOLUTION STRUCTURE OF THE DNA DUPLEX CONTAINING DNA/RNA HYBRID REGION, D(GGAGA)R(UGAC)/D(GTCATCTCC)
GTCATCTCC
>pdb|1DHH|B Chain B, NMR SOLUTION STRUCTURE OF THE DNA DUPLEX CONTAINING DNA/RNA HYBRID REGION, D(GG)R(AGAU)D(GAC)/D(GTCATCTCC)
GTCATCTCC
>pdb|1DXA|B Chain B, BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
CTCGGGACC
>pdb|1DXA|A Chain A, BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
GGTCACGAG
>pdb|199D|B Chain B, Solution structure of the monoalkylated mitomycin c-DNA complex
ACGACGTGC
>pdb|199D|A Chain A, Solution structure of the monoalkylated mitomycin c-DNA complex
NCACGTCNT
>pdb|7Q5B|s Chain s, Cryo-EM structure of Ty3 retrotransposon targeting a TFIIIB-bound tRNA gene
NATTTGTTG
>pdb|7S02|B Chain B, Crystal structure of FBF-2 in complex with LST-1 site A peptide and FBE RNA
NGTACTATA
>pdb|7KT2|T Chain T, DNA Polymerase Mu, dGTP:At Product State Ternary Complex, 50 mM Mn2+ (225min)
CGGCATACG
>pdb|7KT1|T Chain T, DNA Polymerase Mu, dGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (180min)
CGGCATACG
>pdb|7KT0|T Chain T, DNA Polymerase Mu, dGTP:At Ground State Ternary Complex, 50 mM Mg2+ (60min)
CGGCATACG
>pdb|7KSZ|T Chain T, DNA Polymerase Mu, dGTP:At Pre-Catalytic Ground State Ternary Complex, 10 mM Ca2+ (960min)
CGGCATACG
>pdb|7KSU|T Chain T, DNA Polymerase Mu, dGTP:Ct Product State Ternary Complex, 10 mM Mn2+ (4min)
CGGCCTACG
>pdb|1ID9|B Chain B, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF RH(NH3)6+++
GCTTCGGCN
>pdb|1ID9|A Chain A, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF RH(NH3)6+++
GCTTCGGCN
>pdb|1ICG|B Chain B, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF IR(NH3)6+++
GCTTCGGCN
>pdb|1ICG|A Chain A, STRUCTURE OF THE HYBRID RNA/DNA R-GCUUCGGC-D[F]U IN PRESENCE OF IR(NH3)6+++
GCTTCGGCN
>PA278398.1 JP 2021518747-A/15: Gold Optimized CAR T-cells
CTGCTGCTG
>PA278395.1 JP 2021518747-A/12: Gold Optimized CAR T-cells
TTATTTATT
>PA278390.1 JP 2021518747-A/7: Gold Optimized CAR T-cells
NNTTNNTTT
>pdb|7M50|qq Chain qq, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTTT
>pdb|7M50|ll Chain ll, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTTT
>pdb|7M50|i Chain i, Crystallographic structure of a cubic crystal form of STMV grown from ammonium sulfate
NTTTTTTTT
>pdb|5BKN|kk Chain kk, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NTTTTTTTT
>pdb|5BKN|WW Chain WW, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NTTTTTTTT
>pdb|5BKN|m Chain m, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NTTTTTTTT
>pdb|5BKN|V Chain V, Crystallographic structure of a cubic crystal form of STMV (84.5 degree rotation) grown from chloride
NAAAAAAAA
>pdb|7OJN|M Chain M, Lassa virus L protein in an elongation conformation [ELONGATION]
NACGCACAG
>pdb|7OJK|E Chain E, Lassa virus L protein bound to the distal promoter duplex [DISTAL-PROMOTER]
NCCTAGGAT
>OF232160.1 KR 1020210022650-A/61: ANTI-FACTOR XII/XIIA ANTIBODIES AND USES THEREOF
GGTGCATCC
>OF232152.1 KR 1020210022650-A/45: ANTI-FACTOR XII/XIIA ANTIBODIES AND USES THEREOF
AAGGTTTCT
>OF232144.1 KR 1020210022650-A/29: ANTI-FACTOR XII/XIIA ANTIBODIES AND USES THEREOF
ACTGCATCC
>OF232136.1 KR 1020210022650-A/13: ANTI-FACTOR XII/XIIA ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF232051.1 KR 1020210035806-A/138: SOLUBILIZED APYRASES, METHODS AND USE
GCCCCTACC
>OF231809.1 KR 1020210023982-A/69: BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF231797.1 KR 1020210023982-A/45: BISPECIFIC ANTI-PSMA X ANTI-CD28 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF190732.1 KR 1020210008008-A/463: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190724.1 KR 1020210008008-A/447: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190716.1 KR 1020210008008-A/431: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GTTGCATCC
>OF190684.1 KR 1020210008008-A/365: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190660.1 KR 1020210008008-A/317: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
AAGGCGTCT
>OF190652.1 KR 1020210008008-A/301: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATTC
>OF190644.1 KR 1020210008008-A/285: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
AAGATTTCT
>OF190636.1 KR 1020210008008-A/269: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190628.1 KR 1020210008008-A/253: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTACATCC
>OF190620.1 KR 1020210008008-A/237: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190612.1 KR 1020210008008-A/221: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190604.1 KR 1020210008008-A/205: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
AAGGCGTCT
>OF190596.1 KR 1020210008008-A/189: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190588.1 KR 1020210008008-A/173: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190580.1 KR 1020210008008-A/157: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
TATACATCC
>OF190572.1 KR 1020210008008-A/141: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190564.1 KR 1020210008008-A/125: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190556.1 KR 1020210008008-A/109: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCGTCC
>OF190548.1 KR 1020210008008-A/93: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190540.1 KR 1020210008008-A/77: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190532.1 KR 1020210008008-A/61: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GGTGCATCC
>OF190524.1 KR 1020210008008-A/45: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190516.1 KR 1020210008008-A/29: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
GCTGCATCC
>OF190508.1 KR 1020210008008-A/13: ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF
ACTGCATCC
>OF268285.1 KR 1020210049124-A/33: ENGINEERED TARGET SPECIFIC BASE EDITORS
TGTCCCTGT
>OF268284.1 KR 1020210049124-A/32: ENGINEERED TARGET SPECIFIC BASE EDITORS
TGTTCCTGT
>OF268283.1 KR 1020210049124-A/31: ENGINEERED TARGET SPECIFIC BASE EDITORS
TGTTTCTGT
>OF268282.1 KR 1020210049124-A/30: ENGINEERED TARGET SPECIFIC BASE EDITORS
TGTGTCTGT
>OF187866.1 KR 1020210005090-A/72: CHIMERIC VECTORS
TAGTTATAG
>OF187859.1 KR 1020210005090-A/63: CHIMERIC VECTORS
GCCGCCACC
>OF266848.1 KR 1020210043624-A/13: A PHARMACEUTICAL COMPOSITION FOR SAFE AND EFFECTIVE TREATMENT OF KNEE AND/OR HIP PAIN
GCTGCATTC
>OF134756.1 KR 1020210036742-A/32: Chimeric Antigen Receptor comprising Anti-c-Met Antibody or Antigen Binding Fragment Thereof, and Uses Thereof
GCGGCCGCA
>OF134481.1 KR 1020210032095-A/2: Composition for temperature sensors including graphene oxide, DNAzyme and PNA and temperature sensing method using the same
ACCCGCCCT
>OF216785.1 KR 1020210031680-A/162: 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TACACCTCC
>OF216784.1 KR 1020210031680-A/161: 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TACACTAGC
>OF216748.1 KR 1020210031680-A/98: 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TGGGCCTCT
>OF216729.1 KR 1020210031680-A/54: 3-(5-HYDROXY-1-OXOISOINDOLIN-2-YL) PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF IKAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TGGGCCTCT
>OF255262.1 KR 1020210034032-A/85: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF255258.1 KR 1020210034032-A/77: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF255250.1 KR 1020210034032-A/61: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
GCTGCAACC
>OF255242.1 KR 1020210034032-A/45: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
ACTGCATCC
>OF255234.1 KR 1020210034032-A/29: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF255226.1 KR 1020210034032-A/13: BISPECIFIC ANTI-BCMA x ANTI-CD3 ANTIBODIES AND USES THEREOF
GCTGCATCC
>OF293479.1 KR 1020210066947-A/11: A Fusion Protein Comprising DNA Binding Protein Containing PPR Motif
TCTATCACT
>OF255157.1 KR 1020210035832-A/77: CHIMERIC ANTIGEN RECEPTORS WITH BCMA SPECIFICITY AND USES THEREOF
GCTGCATCC
>OF255149.1 KR 1020210035832-A/61: CHIMERIC ANTIGEN RECEPTORS WITH BCMA SPECIFICITY AND USES THEREOF
GCTGCAACC
>OF255141.1 KR 1020210035832-A/45: CHIMERIC ANTIGEN RECEPTORS WITH BCMA SPECIFICITY AND USES THEREOF
ACTGCATCC
>OF255133.1 KR 1020210035832-A/29: CHIMERIC ANTIGEN RECEPTORS WITH BCMA SPECIFICITY AND USES THEREOF
GCTGCATCC
>OF255125.1 KR 1020210035832-A/13: CHIMERIC ANTIGEN RECEPTORS WITH BCMA SPECIFICITY AND USES THEREOF
GCTGCATCC
>OF252016.1 KR 1020210031923-A/162: 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TACACCTCC
>OF252015.1 KR 1020210031923-A/161: 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TACACTAGC
>OF251979.1 KR 1020210031923-A/98: 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TGGGCCTCT
>OF251960.1 KR 1020210031923-A/54: 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF I KAROS FAMILY ZINC FINGER 2 (IKZF2)-DEPENDENT DISEASES
TGGGCCTCT
>OF290653.1 KR 1020210077732-A/302: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CGGAAGGGC
>OF290651.1 KR 1020210077732-A/300: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CGCTCCACC
>OF290649.1 KR 1020210077732-A/298: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CCCAGCCTC
>OF290633.1 KR 1020210077732-A/282: PROGRAMMABLE DNA BASE EDITING BY NME2CAS9-DEAMINASE FUSION PROTEINS
CTCTAGACG
>OF210237.1 KR 1020210056317-A/9: A gene construct for diagnosing and treating of tumors
ATGCATAAT
>OF288170.1 KR 1020210061439-A/48: ENGINEERING T-CELL RECEPTORS
TCTGCTAGC
>OF287644.1 KR 1020210048605-A/14: COMPOSITIONS FEATURING AN ATTENUATED NEWCASTLE DISEASE VIRUS AND METHODS OF USE FOR TREATING NEOPLASIA
ACGGGTAGA
>OF208996.1 KR 1020210022606-A/7: A METHOD CODING STANDARDIZATION OF DNA AND A BIOTECHNOLOGICAL USE OF THE METHOD
GCGGTGGCG
>OF247444.1 KR 1020210016078-A/2302: CHIRAL CONTROL
CAGGTAAGT
>OF208266.1 KR 1020210021493-A/176: MUC16 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
GGAAGCGGA
>OF245178.1 KR 1020210016078-A/33: CHIRAL CONTROL
CAACGTTCT
>OF244513.1 KR 1020210016067-A/31: ANTIGEN BINDING CONSTRUCTS TO CD8
GGCGGCTGC
>OF244160.1 KR 1020210032401-A/165: ANTI-IL36R ANTIBODIES
GCTGCATCC
>OF244152.1 KR 1020210032401-A/149: ANTI-IL36R ANTIBODIES
GCTGCATCC
>OF244140.1 KR 1020210032401-A/125: ANTI-IL36R ANTIBODIES
GCTGCATCC
>OF244132.1 KR 1020210032401-A/109: ANTI-IL36R ANTIBODIES
GCTGCATCC
>OF244124.1 KR 1020210032401-A/93: ANTI-IL36R ANTIBODIES
GCTGCATCC
>OF244116.1 KR 1020210032401-A/77: ANTI-IL36R ANTIBODIES
AAGGCGTCT
>OF244108.1 KR 1020210032401-A/61: ANTI-IL36R ANTIBODIES
AATGTAGCC
>OF244100.1 KR 1020210032401-A/45: ANTI-IL36R ANTIBODIES
AATGCAGCA
>OF244092.1 KR 1020210032401-A/29: ANTI-IL36R ANTIBODIES
AATGTAGCC
>OF244084.1 KR 1020210032401-A/13: ANTI-IL36R ANTIBODIES
AATGCAGCA
>OF242288.1 KR 1020210043562-A/275: ROR-1 SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
GGAAGCGGA
>OF202512.1 KR 1020210018323-A/74: CIRCULAR RNA FOR TRANSLATION IN EUKARYOTIC CELLS
TGTAGGACT
>OF202511.1 KR 1020210018323-A/73: CIRCULAR RNA FOR TRANSLATION IN EUKARYOTIC CELLS
GGTTCTACA
>OF202310.1 KR 1020210014668-A/755: ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
TACACCTCC
>OF202309.1 KR 1020210014668-A/754: ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
TACACTAGC
>OF202273.1 KR 1020210014668-A/637: ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
TGGGCCTCT
>OF202254.1 KR 1020210014668-A/533: ENTPD2 ANTIBODIES, COMBINATION THERAPIES, AND METHODS OF USING THE ANTIBODIES AND COMBINATION THERAPIES
TGGGCCTCT
>OF240930.1 KR 1020210013303-A/2803: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
TGGGAGGTC
>OF240891.1 KR 1020210013303-A/2764: USING TRUNCATED GUIDE RNAS (TRU-GRNAS) TO INCREASE SPECIFICITY FOR RNA-GUIDED GENOME EDITING
CCAAAGCCC
>OF201285.1 KR 1020210013133-A/10: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
ACAGGAGCA
>OF201284.1 KR 1020210013133-A/9: HYBRIDIZING ALL-LNA OLIGONUCLEOTIDES
TGCTCCTGT
>OF278971.1 KR 1020210064264-A/13: IMMUNODEFICIENT MOUSE
CGCTATGCT
>OF278970.1 KR 1020210064264-A/12: IMMUNODEFICIENT MOUSE
ACGCTAAGC
>OF199093.1 KR 1020210010916-A/285: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF199085.1 KR 1020210010916-A/269: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF199077.1 KR 1020210010916-A/253: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF199069.1 KR 1020210010916-A/237: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF199061.1 KR 1020210010916-A/221: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTCCATCC
>OF199053.1 KR 1020210010916-A/205: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF199045.1 KR 1020210010916-A/189: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF199037.1 KR 1020210010916-A/173: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF277384.1 KR 1020210037757-A/11: A Method for Designing a Fusion Protein Comprising DNA Binding Protein Containing PPR Motif
TCTATCACT
>OF199029.1 KR 1020210010916-A/157: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF199021.1 KR 1020210010916-A/141: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF199013.1 KR 1020210010916-A/125: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF199005.1 KR 1020210010916-A/109: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GTAGCATCC
>OF198997.1 KR 1020210010916-A/93: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF198989.1 KR 1020210010916-A/77: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GCTGCATCC
>OF198981.1 KR 1020210010916-A/61: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF198973.1 KR 1020210010916-A/45: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGCATCC
>OF198965.1 KR 1020210010916-A/29: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGGATCC
>OF198957.1 KR 1020210010916-A/13: ANTI-CD63 ANTIBODIES, CONJUGATES, AND USES THEREOF
GGTGTATTC
>OF198878.1 KR 1020210020031-A/145: NON-HUMAN ANIMALS CAPABLE OF DH-DH REARRANGEMENT IN THE IMMUNOGLOBULIN HEAVY CHAIN CODING SEQUENCES
ACAAAAACC
>OF237129.1 KR 1020210041557-A/35: ANTIBODIES AGAINST CAMPYLOBACTER SPECIES
AAAGACAGT
>OF237121.1 KR 1020210041557-A/19: ANTIBODIES AGAINST CAMPYLOBACTER SPECIES
GCTGCAACC
>OF237996.1 KR 1020210027389-A/53: COMPOSITIONS AND METHODS FOR GENOMIC EDITING BY INSERTION OF DONOR POLYNUCLEOTIDES
TTTTTTTCT
>OF275339.1 KR 1020210049871-A/222: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GCTGCATCC
>OF275331.1 KR 1020210049871-A/206: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275323.1 KR 1020210049871-A/190: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GTTGCATCC
>OF275315.1 KR 1020210049871-A/174: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GCTGCATCC
>OF275307.1 KR 1020210049871-A/158: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GCTGCATCC
>OF275299.1 KR 1020210049871-A/142: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275291.1 KR 1020210049871-A/126: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GTTGCATCC
>OF275283.1 KR 1020210049871-A/110: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275275.1 KR 1020210049871-A/94: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275267.1 KR 1020210049871-A/78: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275259.1 KR 1020210049871-A/62: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275251.1 KR 1020210049871-A/46: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GATGCATCC
>OF275243.1 KR 1020210049871-A/30: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GGTGCATCC
>OF275235.1 KR 1020210049871-A/14: METHODS AND COMPOSITIONS FOR TREATING SUBJECTS HAVING RHEUMATOID ARTHRITIS
GGTGCATCC
>OF275191.1 KR 1020210049863-A/29: ANTI-FC EPSILON-R1 ALPHA (FCER1A) ANTIBODIES, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND FCER1A AND CD3, AND USES THEREOF
GCTGCATCC
>pdb|7NQH|AX Chain AX, 55S mammalian mitochondrial ribosome with mtRF1a and P-site tRNAMet
ATGTAACAC
>pdb|7LXJ|C Chain C, Bacillus cereus DNA glycosylase AlkD bound to a duocarmycin SA-adenine nucleobase adduct and DNA containing an abasic site
TGCCTTTGC
>pdb|7LXJ|B Chain B, Bacillus cereus DNA glycosylase AlkD bound to a duocarmycin SA-adenine nucleobase adduct and DNA containing an abasic site
AGCAANGGC
>pdb|7LXH|C Chain C, Bacillus cereus DNA glycosylase AlkD bound to a CC1065-adenine nucleobase adduct and DNA containing an abasic site
TGCCTTTGC
>pdb|7LXH|B Chain B, Bacillus cereus DNA glycosylase AlkD bound to a CC1065-adenine nucleobase adduct and DNA containing an abasic site
AGCAANGGC
>MQ301262.1 Sequence 37 from Patent WO2021229218
TGACTAGCA
>MQ301261.1 Sequence 36 from Patent WO2021229218
TAACAATTA
>MQ301260.1 Sequence 35 from Patent WO2021229218
TAGCAATTA
>MQ301259.1 Sequence 34 from Patent WO2021229218
TGACAATTA
>MQ301236.1 Sequence 11 from Patent WO2021229218
TAACAATTA
>MQ301235.1 Sequence 10 from Patent WO2021229218
TAGCAATTA
>MQ301234.1 Sequence 9 from Patent WO2021229218
TGACAATTA
>MQ301230.1 Sequence 5 from Patent WO2021229218
TTTTTTTAA
>MQ301229.1 Sequence 4 from Patent WO2021229218
TTTTTTTAG
>MQ301228.1 Sequence 3 from Patent WO2021229218
TTTTTTTGA
>MQ300963.1 Sequence 51 from Patent WO2021231366
GGTGCATCC
>MQ300925.1 Sequence 13 from Patent WO2021231366
GATGCATCC
>MQ300744.1 Sequence 39 from Patent WO2021228944
TGNCCNATA
>MQ296243.1 Sequence 157 from Patent WO2021231854
CCRCCATGG
>MQ292105.1 Sequence 18 from Patent WO2021222304
TTATTTAWW
>MQ292103.1 Sequence 16 from Patent WO2021222304
CCRCCATGG
>MQ288644.1 Sequence 142 from Patent WO2021214623
TGGGCCTCT
>pdb|3E54|F Chain F, Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA
NAGAGTCAG
>pdb|3E54|D Chain D, Archaeal Intron-encoded Homing Endonuclease I-Vdi141I Complexed With DNA
NGTAGCCAA
>pdb|1BPS|A Chain A, MINOR CONFORMER OF A BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
GGTCACGAG
>pdb|1BPS|B Chain B, MINOR CONFORMER OF A BENZO[A]PYRENE DIOL EPOXIDE ADDUCT OF DA IN DUPLEX DNA
CTCGGGACC
>pdb|1IJS|N Chain N, CPV (STRAIN D) mutant A300D, complex (VIRAL COAT/DNA), VP2, PH=7.5, T=4 DEGREES C
NCACCCCAA
>MQ265168.1 Sequence 78 from Patent WO2021209743
GCGATTAAG
>MQ265160.1 Sequence 70 from Patent WO2021209743
CTGCACGTA
>MQ265150.1 Sequence 60 from Patent WO2021209743
TACGTGCAG
>MQ265102.1 Sequence 12 from Patent WO2021209743
TGACGTGCT
>MQ265097.1 Sequence 7 from Patent WO2021209743
CTGCACGTA
>MQ263067.1 Sequence 61 from Patent WO2021212096
TGGGCATCT
>MQ263041.1 Sequence 35 from Patent WO2021212096
GCTGCATCC
>MQ261840.1 Sequence 463 from Patent WO2021211984
GCTGCATCC
>MQ261824.1 Sequence 447 from Patent WO2021211984
GCTGCATCC
>MQ261808.1 Sequence 431 from Patent WO2021211984
GTTGCATCC
>MQ261742.1 Sequence 365 from Patent WO2021211984
GGTGCATCC
>MQ261694.1 Sequence 317 from Patent WO2021211984
AAGGCGTCT
>MQ261678.1 Sequence 301 from Patent WO2021211984
GCTGCATTC
>MQ261662.1 Sequence 285 from Patent WO2021211984
AAGATTTCT
>MQ261646.1 Sequence 269 from Patent WO2021211984
GGTGCATCC
>MQ261630.1 Sequence 253 from Patent WO2021211984
GCTACATCC
>MQ261614.1 Sequence 237 from Patent WO2021211984
GGTGCATCC
>MQ261598.1 Sequence 221 from Patent WO2021211984
GGTGCATCC
>MQ261582.1 Sequence 205 from Patent WO2021211984
AAGGCGTCT
>MQ261566.1 Sequence 189 from Patent WO2021211984
GCTGCATCC
>MQ261550.1 Sequence 173 from Patent WO2021211984
GCTGCATCC
>MQ261534.1 Sequence 157 from Patent WO2021211984
TATACATCC
>MQ261518.1 Sequence 141 from Patent WO2021211984
GCTGCATCC
>MQ261502.1 Sequence 125 from Patent WO2021211984
GGTGCATCC
>MQ261486.1 Sequence 109 from Patent WO2021211984
GCTGCGTCC
>MQ261470.1 Sequence 93 from Patent WO2021211984
GCTGCATCC
>MQ261454.1 Sequence 77 from Patent WO2021211984
GCTGCATCC
>MQ261438.1 Sequence 61 from Patent WO2021211984
GGTGCATCC
>MQ261422.1 Sequence 45 from Patent WO2021211984
GCTGCATCC
>MQ261406.1 Sequence 29 from Patent WO2021211984
GCTGCATCC
>MQ261390.1 Sequence 13 from Patent WO2021211984
ACTGCATCC
>pdb|1M5V|P Chain P, Transition State Stabilization by a Catalytic RNA
GTCCTCTCC
>pdb|1M5V|M Chain M, Transition State Stabilization by a Catalytic RNA
GTCCTCTCC
>pdb|1M5P|P Chain P, Transition State Stabilization by a Catalytic RNA
NTCCTCTCC
>pdb|1M5P|M Chain M, Transition State Stabilization by a Catalytic RNA
NTCCTCTCC
>PA269005.1 WO 2021132661-A/4: Production method for library, cyclic peptide, binding agents for FXIIa and IFNGR1
AGCCTGGTA
>PA268716.1 WO 2021132528-A/94: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGGTCGTT
>PA268692.1 WO 2021132528-A/70: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGCCC
>PA268691.1 WO 2021132528-A/69: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGATC
>PA268681.1 WO 2021132528-A/59: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGGACGTT
>PA268680.1 WO 2021132528-A/58: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGTTCGTT
>PA268679.1 WO 2021132528-A/57: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGTACGTT
>PA268678.1 WO 2021132528-A/56: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGATCGTT
>PA268677.1 WO 2021132528-A/55: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGAACGTT
>PA268649.1 WO 2021132528-A/27: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
CCGACGTTC
>PA268648.1 WO 2021132528-A/26: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGCCGTTC
>PA268647.1 WO 2021132528-A/25: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGCCGTCT
>PA268645.1 WO 2021132528-A/23: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCTACGTTC
>PA268644.1 WO 2021132528-A/22: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGTTT
>PA268642.1 WO 2021132528-A/20: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGGCGTTC
>PA268641.1 WO 2021132528-A/19: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGACGTTC
>PA268634.1 WO 2021132528-A/12: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGAGCGTT
>PA268626.1 WO 2021132528-A/4: OLIGODEOXYNUCLEOTIDE CONTAINING SHORT CPG ODN LINKED WITH POLYDEOXYADENYLIC ACID, COMPLEX CONTAINING SAID OLIGODEOXYNUCLEOTIDE, AND USE THEREOF
TCGTCGTTC
>PA268584.1 WO 2021132166-A/143: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
CTGGCCTCC
>PA268578.1 WO 2021132166-A/137: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
CTGGCATCC
>PA268572.1 WO 2021132166-A/131: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
GACACCAGC
>PA268566.1 WO 2021132166-A/125: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
GATACATCC
>PA268560.1 WO 2021132166-A/119: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
TCTGCCTCC
>PA268554.1 WO 2021132166-A/113: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
TCTGCATCC
>PA268548.1 WO 2021132166-A/107: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
TTGGCCTCC
>PA268542.1 WO 2021132166-A/101: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
CTGGCATCT
>PA268536.1 WO 2021132166-A/95: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
GACACATCC
>PA268530.1 WO 2021132166-A/89: A METHOD FOR PRODUCING ERIBULIN-BASED ANTIBODY-DRUG CONJUGATES
GGCACATCC
>MQ253741.1 Sequence 538 from Patent WO2021205216
GGGGACATC
>MQ253661.1 Sequence 458 from Patent WO2021205216
GGGGACATC
>MQ253621.1 Sequence 418 from Patent WO2021205216
GGCGACATC
>MQ253581.1 Sequence 378 from Patent WO2021205216
GGGGACATC
>MQ253541.1 Sequence 338 from Patent WO2021205216
GGGGACATC
>MQ253501.1 Sequence 298 from Patent WO2021205216
GGGGACATC
>MQ253461.1 Sequence 258 from Patent WO2021205216
GGGGACATC
>MQ253421.1 Sequence 218 from Patent WO2021205216
GGGGACATC
>MQ253381.1 Sequence 178 from Patent WO2021205216
GGGGACATC
>MQ253341.1 Sequence 138 from Patent WO2021205216
GGGGACATC
>MQ253301.1 Sequence 98 from Patent WO2021205216
GGGGACATC
>MQ253261.1 Sequence 58 from Patent WO2021205216
GGGGACATC
>MQ253221.1 Sequence 18 from Patent WO2021205216
GGGGACATC
>MQ246912.1 Sequence 36 from Patent EP3894545
ATGCTCGAG
>MQ240096.1 Sequence 25 from Patent EP3891274
ATAAGTGAA
>MQ238411.1 Sequence 25 from Patent EP3891175
ATAAGTGAA
>MQ236769.1 Sequence 20 from Patent EP3891182
GCCGCCACC
>MQ219614.1 Sequence 26 from Patent WO2021191333
TCNTNNTCT
>MQ220575.1 Sequence 123 from Patent WO2021191628
GCGATTAAG
>MQ220565.1 Sequence 113 from Patent WO2021191628
CTGCACGTA
>MQ220556.1 Sequence 104 from Patent WO2021191628
TACGTGCAG
>MQ220465.1 Sequence 12 from Patent WO2021191628
TGACGTGCT
>MQ220460.1 Sequence 7 from Patent WO2021191628
CTGCACGTA
>pdb|7O1A|B7 Chain B7, Cryo-EM structure of an Escherichia coli TnaC(R23F)-ribosome complex stalled in response to L-tryptophan
NGCCCGTGA
>pdb|7M8E|3 Chain 3, E.coli RNAP-RapA elongation complex
NTCGGCTCA
>pdb|3EZ5|E Chain E, Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA, dCTP, and zinc (closed form).
CCTGACTCG
>pdb|3EZ5|B Chain B, Cocrystal structure of Bacillus fragment DNA polymerase I with duplex DNA, dCTP, and zinc (closed form).
CCTGACTCG
>pdb|3BO3|D Chain D, A relaxed active site following exon ligation by a group I intron
CATACGGCC
>pdb|3BSO|T Chain T, Norwalk Virus polymerase bound to cytidine 5'-triphosphate and primer-template RNA
NGCCCGGGC
>pdb|3BSN|T Chain T, Norwalk Virus polymerase bound to 5-nitrocytidine triphosphate and primer-template RNA
TGCCCGGGN
>pdb|2FQZ|H Chain H, Metal-depleted Ecl18kI in complex with uncleaved DNA
GCCCTGGCG
>pdb|2FQZ|G Chain G, Metal-depleted Ecl18kI in complex with uncleaved DNA
CGCCAGGGC
>pdb|2FQZ|F Chain F, Metal-depleted Ecl18kI in complex with uncleaved DNA
GCCCTGGCG
>pdb|2FQZ|E Chain E, Metal-depleted Ecl18kI in complex with uncleaved DNA
CGCCAGGGC
>pdb|2GB7|H Chain H, Metal-depleted Ecl18kI in complex with uncleaved, modified DNA
GCCCTGGCG
>pdb|2GB7|G Chain G, Metal-depleted Ecl18kI in complex with uncleaved, modified DNA
CGCCAGGGC
>pdb|2GB7|F Chain F, Metal-depleted Ecl18kI in complex with uncleaved, modified DNA
GCCCTGGCG
>pdb|2GB7|E Chain E, Metal-depleted Ecl18kI in complex with uncleaved, modified DNA
CGCCAGGGC
>pdb|1YQK|C Chain C, Human 8-oxoguanine glycosylase crosslinked with guanine containing DNA
NAGGTCTAC
>pdb|6KI3|F Chain F, The crystal structure of AsfvAP:dF commplex
GCAGCGTCC
>pdb|6KI3|C Chain C, The crystal structure of AsfvAP:dF commplex
GCAGCGTCC
>pdb|3HT3|E Chain E, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus V713P mutant bound to G:dCTP
CGATCACGN
>pdb|3HT3|B Chain B, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus V713P mutant bound to G:dCTP
CGATCACGN
>pdb|3HPO|B Chain B, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus Y714S mutant bound to G:T mismatch
CGATCACGN
>pdb|3HP6|E Chain E, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus F710Y mutant bound to G:T mismatch
CGATCACGN
>pdb|3HP6|B Chain B, Crystal structure of fragment DNA polymerase I from Bacillus stearothermophilus F710Y mutant bound to G:T mismatch
CGATCACGN
>pdb|3H5Y|T Chain T, Norovirus polymerase+primer/template+CTP complex at 6 mM MnCl2
NGCCCGGGC
>pdb|3H5X|T Chain T, Crystal Structure of 2'-amino-2'-deoxy-cytidine-5'-triphosphate bound to Norovirus GII RNA polymerase
NGCCCGGGC
>MQ206784.1 Sequence 17 from Patent WO2021183675
GCTGCATCC
>MQ206055.1 Sequence 17 from Patent WO2021183207
GCTGCATCC
>MQ205087.1 Sequence 30 from Patent WO2021181108
GCAGTGGCG
>MQ202746.1 Sequence 13 from Patent WO2021178814
GCTGCATCC
>MQ203446.1 Sequence 11 from Patent EP3876987
AAAGTTTCC
>PA268059.1 JP 2021509821-A/22: A Method for Amplifying Target Nucleic Acid and Composition for Amplifying Target Nucleic Acid
CACCGCTGG
>MQ173415.1 Sequence 533 from Patent WO2021171260
TGGGCCTCT
>MQ180453.1 Sequence 21 from Patent WO2021174113
GCTGCATCC
>MQ169114.1 Sequence 62 from Patent WO2021167908
GCTGCATCC
>MQ169098.1 Sequence 46 from Patent WO2021167908
GCCACATCC
>MQ169082.1 Sequence 30 from Patent WO2021167908
CTTGTATCC
>MQ169066.1 Sequence 14 from Patent WO2021167908
AGCACATCC
>MQ165619.1 Sequence 21 from Patent WO2021156370
TTTTTTTTT
>MQ165615.1 Sequence 17 from Patent WO2021156370
TTTTTTTTT
>MQ165605.1 Sequence 7 from Patent WO2021156370
TTTTTTTTT
>MQ165601.1 Sequence 3 from Patent WO2021156370
TTTTTTTTT
>MQ164349.1 Sequence 66 from Patent WO2021156316
TACCGACAT
>MQ164318.1 Sequence 35 from Patent WO2021156316
GGCCAATCT
>MQ164313.1 Sequence 30 from Patent WO2021156316
CTGAGTCAG
>MQ164312.1 Sequence 29 from Patent WO2021156316
CCTGAGTCA
>MQ164311.1 Sequence 28 from Patent WO2021156316
ATTGACTCA
>MQ164310.1 Sequence 27 from Patent WO2021156316
TTTGAGTCA
>MQ164309.1 Sequence 26 from Patent WO2021156316
GTGACTCAG
>MQ164308.1 Sequence 25 from Patent WO2021156316
ATGACTCAA
>MQ164307.1 Sequence 24 from Patent WO2021156316
GTTGACTCA
>MQ164306.1 Sequence 23 from Patent WO2021156316
ATTGAGTCA
>MQ164305.1 Sequence 22 from Patent WO2021156316
CTGAGTCAA
>MQ164304.1 Sequence 21 from Patent WO2021156316
CCTGAGTCA
>MQ164303.1 Sequence 20 from Patent WO2021156316
GTTGAGTCA
>MQ164302.1 Sequence 19 from Patent WO2021156316
ACTGACTCA
>MQ164301.1 Sequence 18 from Patent WO2021156316
ATGACTCAG
>MQ164300.1 Sequence 17 from Patent WO2021156316
AATGAGTCA
>MQ164299.1 Sequence 16 from Patent WO2021156316
GTGAGTCAG
>MQ163616.1 Sequence 302 from Patent EP3867367
CGGAAGGGC
>MQ163614.1 Sequence 300 from Patent EP3867367
CGCTCCACC
>MQ163612.1 Sequence 298 from Patent EP3867367
CCCAGCCTC
>MQ163596.1 Sequence 282 from Patent EP3867367
CTCTAGACG
>MQ159740.1 Sequence 11 from Patent WO2021159130
TTATTTAWW
>MQ159738.1 Sequence 9 from Patent WO2021159130
CCRCCATGG
>MQ159366.1 Sequence 130 from Patent WO2021159040
TTATTTAWW
>MQ159364.1 Sequence 128 from Patent WO2021159040
CCRCCATGG
>MQ158482.1 Sequence 330 from Patent WO2021163170
AAGGTTTCT
>MQ158462.1 Sequence 310 from Patent WO2021163170
GTTGCATCC
>MQ158432.1 Sequence 280 from Patent WO2021163170
GAGATTTCT
>MQ158398.1 Sequence 246 from Patent WO2021163170
ACTGCATCC
>MQ158366.1 Sequence 214 from Patent WO2021163170
TGGGCATCT
>MQ158329.1 Sequence 177 from Patent WO2021163170
GCTGCATCC
>MQ158291.1 Sequence 139 from Patent WO2021163170
AAGGCGTCT
>MQ158273.1 Sequence 121 from Patent WO2021163170
ACGATTTCT
>MQ158259.1 Sequence 107 from Patent WO2021163170
ACGGTTTCT
>MQ158239.1 Sequence 87 from Patent WO2021163170
CAGGTTTCT
>MQ158215.1 Sequence 63 from Patent WO2021163170
GATGCATCC
>MQ158203.1 Sequence 51 from Patent WO2021163170
GATGTATTT
>MQ158185.1 Sequence 33 from Patent WO2021163170
GATGTATCC
>MQ158165.1 Sequence 13 from Patent WO2021163170
GGTGCATCC
>MQ157790.1 Sequence 53 from Patent WO2021163076
GCTGCATCC
>MQ157770.1 Sequence 33 from Patent WO2021163076
GGTGCATCC
>MQ157750.1 Sequence 13 from Patent WO2021163076
GTTGCATCC
>MQ155895.1 Sequence 1 from Patent EP3868774
TGGTTGTGG
>MQ155689.1 Sequence 124 from Patent EP3868783
GCGGCCGCA
>MQ153560.1 Sequence 16 from Patent EP3868399
GCCGCCGCC
>pdb|6VFC|T Chain T, DNA Polymerase Mu, 8-oxorGTP:Ct Product State Ternary Complex, 50 mM Mn2+ (2160 min)
CGGCCTACG
>pdb|6VFB|T Chain T, DNA Polymerase Mu, 8-oxorGTP:Ct Reaction State Ternary Complex, 50 mM Mn2+ (960 min)
CGGCCTACG
>pdb|6VFA|T Chain T, DNA Polymerase Mu, 8-oxorGTP:Ct Ground State Ternary Complex, 50 mM Mn2+ (15 min)
CGGCCTACG
>pdb|6VF9|T Chain T, DNA Polymerase Mu, 8-oxorGTP:Ct Ternary Complex, 50 mM Mg2+ (2160 min)
CGGCCTACG
>pdb|6VF8|T Chain T, DNA Polymerase Mu, 8-oxorGTP:Ct Pre-Catalytic Ternary Complex, 20 mM Ca2+ (120 min)
CGGCCTACG
>pdb|6VF7|T Chain T, DNA Polymerase Mu, 8-oxodGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)
CGGCATACG
>pdb|6VF6|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (960 min)
CGGCATACG
>pdb|6VF5|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mn2+ (120 min)
CGGCATACG
>pdb|6VF4|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mn2+ (30 min)
CGGCATACG
>pdb|6VF3|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Ground State Ternary Complex, 50 mM Mn2+ (15 min)
CGGCATACG
>pdb|6VF2|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (960 min)
CGGCATACG
>pdb|6VF1|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Product State Ternary Complex, 50 mM Mg2+ (120 min)
CGGCATACG
>pdb|6VF0|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Reaction State Ternary Complex, 50 mM Mg2+ (30 min)
CGGCATACG
>pdb|6VEZ|T Chain T, DNA Polymerase Mu, 8-oxorGTP:At Pre-Catalytic Ternary Complex, 20 mM Ca2+ (60 min)
CGGCATACG
>pdb|7ODF|G Chain G, Structure of the mini-RNA-guided endonuclease CRISPR-Cas_phi3
NTAATTCAG
>MQ147489.1 Sequence 110 from Patent EP3861105
TTNNNNNAA
>MQ144986.1 Sequence 28 from Patent WO2021152587
GGGGCGGGG
>MQ144983.1 Sequence 25 from Patent WO2021152587
ACCGGAWRY
>MQ144980.1 Sequence 22 from Patent WO2021152587
RCCGGAAGY
>MQ144972.1 Sequence 14 from Patent WO2021152587
ASCACRTGG
>MQ143731.1 Sequence 113 from Patent EP3861015
CTGGTGTCT
>MQ143725.1 Sequence 107 from Patent EP3861015
AAAGTTTCC
>MQ143719.1 Sequence 101 from Patent EP3861015
TGGGCATCC
>MQ141315.1 Sequence 13 from Patent EP3861854
CGCTATGCT
>MQ141314.1 Sequence 12 from Patent EP3861854
ACGCTAAGC
>MQ136514.1 Sequence 13 from Patent WO2021151031
AAGGCGTCT
>MQ136730.1 Sequence 229 from Patent WO2021151031
GGTGCATCC
>MQ136714.1 Sequence 213 from Patent WO2021151031
AAGGCGTCT
>MQ136698.1 Sequence 197 from Patent WO2021151031
GCTGCATCC
>MQ136682.1 Sequence 181 from Patent WO2021151031
GCTGCATCC
>MQ136666.1 Sequence 165 from Patent WO2021151031
GCTGCATCC
>MQ136650.1 Sequence 149 from Patent WO2021151031
GCTGCATCC
>MQ136634.1 Sequence 133 from Patent WO2021151031
GCTACATCC
>MQ136618.1 Sequence 117 from Patent WO2021151031
AAGATTTCT
>MQ136602.1 Sequence 101 from Patent WO2021151031
GGTGCATCC
>MQ136586.1 Sequence 85 from Patent WO2021151031
ACTGCATCC
>MQ136570.1 Sequence 69 from Patent WO2021151031
GCTGCATCC
>MQ136562.1 Sequence 61 from Patent WO2021151031
GCTGCATCC
>MQ136546.1 Sequence 45 from Patent WO2021151031
AAGGCGTCT
>MQ136530.1 Sequence 29 from Patent WO2021151031
GCTGCGTCC
>MQ133991.1 Sequence 49 from Patent WO2021150829
GCTGCATCC
>MQ133973.1 Sequence 31 from Patent WO2021150829
TGGGCATCT
>MQ133955.1 Sequence 13 from Patent WO2021150829
GCTGCATCC
>MQ125110.1 Sequence 196 from Patent EP3853377
GATAAAAAC
>MQ125109.1 Sequence 195 from Patent EP3853377
GGTGCATCC
>MQ125108.1 Sequence 194 from Patent EP3853377
GATGATACC
>MQ125107.1 Sequence 193 from Patent EP3853377
GAGGATGAC
>MQ125106.1 Sequence 192 from Patent EP3853377
GGTGCATCT
>MQ125105.1 Sequence 191 from Patent EP3853377
GATGCCTCA
>MQ125104.1 Sequence 190 from Patent EP3853377
GATGTCAGT
>MQ125103.1 Sequence 189 from Patent EP3853377
GAGGTCAAT
>MQ125102.1 Sequence 188 from Patent EP3853377
GATGCATCC
>MQ125101.1 Sequence 187 from Patent EP3853377
GATGCATCC
>MQ125100.1 Sequence 186 from Patent EP3853377
GGTGCCTCC
>MQ125099.1 Sequence 185 from Patent EP3853377
GAGGGCAGT
>MQ125098.1 Sequence 184 from Patent EP3853377
GATGTCAGT
>MQ125097.1 Sequence 183 from Patent EP3853377
GAGGATAAC
>MQ117816.1 Sequence 139 from Patent WO2021146328
TGGGCATCT
>MQ116732.1 Sequence 299 from Patent WO2021146336
GCTGCATCC
>MQ116716.1 Sequence 283 from Patent WO2021146336
GCTGCATCC
>MQ116700.1 Sequence 267 from Patent WO2021146336
GCTGCATCC
>MQ116684.1 Sequence 251 from Patent WO2021146336
GCTGCATCC
>MQ116668.1 Sequence 235 from Patent WO2021146336
GCTGCATCC
>MQ116652.1 Sequence 219 from Patent WO2021146336
TTGGGTTCT
>MQ116636.1 Sequence 203 from Patent WO2021146336
TCTGCATCT
>MQ116620.1 Sequence 187 from Patent WO2021146336
GCTGCATCC
>MQ116604.1 Sequence 171 from Patent WO2021146336
GCTGCATCC
>MQ116588.1 Sequence 155 from Patent WO2021146336
GCTGCATCC
>OF066202.1 KR 1020200091499-A/37: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
GTTTTTGTA
>OF066186.1 KR 1020200091499-A/21: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
TCATTTGAG
>OF066184.1 KR 1020200091499-A/19: ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA
CGATTTGAG
>OF023751.1 KR 1020200130188-A/9: A gene construct for diagnosing and treating of tumors
ATGCATAAT
>OF016650.1 KR 1020200137636-A/55: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTT
>OF016649.1 KR 1020200137636-A/54: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTT
>OF016648.1 KR 1020200137636-A/53: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTTCTG
>OF016647.1 KR 1020200137636-A/52: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTGCTT
>OF016646.1 KR 1020200137636-A/51: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTG
>OF016645.1 KR 1020200137636-A/50: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTG
>OF016644.1 KR 1020200137636-A/49: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTTCTT
>OF016643.1 KR 1020200137636-A/48: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTTCTT
>OF016642.1 KR 1020200137636-A/47: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTGCTT
>OF016641.1 KR 1020200137636-A/46: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTATT
>OF016640.1 KR 1020200137636-A/45: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTATT
>OF016639.1 KR 1020200137636-A/44: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATTTAGT
>OF016638.1 KR 1020200137636-A/43: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTATT
>OF016637.1 KR 1020200137636-A/42: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGTTAGT
>OF016636.1 KR 1020200137636-A/41: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTATGTAGT
>OF016635.1 KR 1020200137636-A/40: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGGTATT
>OF016634.1 KR 1020200137636-A/39: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTAGT
>OF016633.1 KR 1020200137636-A/38: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTAGT
>OF016632.1 KR 1020200137636-A/37: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTAGT
>OF016631.1 KR 1020200137636-A/36: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTTCCC
>OF016630.1 KR 1020200137636-A/35: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTGTTCCC
>OF016629.1 KR 1020200137636-A/34: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTGTCCC
>OF016628.1 KR 1020200137636-A/33: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTT
>OF016627.1 KR 1020200137636-A/32: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTT
>OF016626.1 KR 1020200137636-A/31: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTTTG
>OF016625.1 KR 1020200137636-A/30: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTT
>OF016624.1 KR 1020200137636-A/29: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTTTG
>OF016623.1 KR 1020200137636-A/28: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTATTGTG
>OF016622.1 KR 1020200137636-A/27: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTT
>OF016621.1 KR 1020200137636-A/26: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTTTG
>OF016620.1 KR 1020200137636-A/25: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGATTGTG
>OF016619.1 KR 1020200137636-A/24: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAGTGTG
>OF016618.1 KR 1020200137636-A/23: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTGTT
>OF016617.1 KR 1020200137636-A/22: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTG
>OF016616.1 KR 1020200137636-A/21: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTG
>OF016615.1 KR 1020200137636-A/20: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTG
>OF016614.1 KR 1020200137636-A/19: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTG
>OF016613.1 KR 1020200137636-A/18: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATTTA
>OF016612.1 KR 1020200137636-A/17: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATTTA
>OF016611.1 KR 1020200137636-A/16: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATTTA
>OF016610.1 KR 1020200137636-A/15: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATGTA
>OF016609.1 KR 1020200137636-A/14: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAATTTA
>OF016608.1 KR 1020200137636-A/13: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATGTA
>OF016607.1 KR 1020200137636-A/12: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATGTA
>OF016606.1 KR 1020200137636-A/11: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTCACG
>OF016605.1 KR 1020200137636-A/10: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTCACG
>OF016604.1 KR 1020200137636-A/9: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATGCACG
>OF098350.1 KR 1020200123165-A/42: CANCER THERAPEUTIC TARGETING USING MUTANT P53-SPECIFIC SIRNAS
TCTCTTGAA
>OF098348.1 KR 1020200123165-A/40: CANCER THERAPEUTIC TARGETING USING MUTANT P53-SPECIFIC SIRNAS
TTCAAGAGA
>OF098166.1 KR 1020200130696-A/32: ANTI-NGF ANTIBODIES AND METHODS THEREOF
AGTGATGGG
>OF098156.1 KR 1020200130696-A/12: ANTI-NGF ANTIBODIES AND METHODS THEREOF
GGTAATGGG
>OF015787.1 KR 1020200137635-A/55: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTT
>OF015786.1 KR 1020200137635-A/54: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTT
>OF015785.1 KR 1020200137635-A/53: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTTCTG
>OF015784.1 KR 1020200137635-A/52: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTGCTT
>OF015783.1 KR 1020200137635-A/51: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTG
>OF015782.1 KR 1020200137635-A/50: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTG
>OF015781.1 KR 1020200137635-A/49: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTTCTT
>OF015780.1 KR 1020200137635-A/48: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTTCTT
>OF015779.1 KR 1020200137635-A/47: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTGCTT
>OF015778.1 KR 1020200137635-A/46: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTATT
>OF015777.1 KR 1020200137635-A/45: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTATT
>OF015776.1 KR 1020200137635-A/44: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATTTAGT
>OF015775.1 KR 1020200137635-A/43: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTATT
>OF015774.1 KR 1020200137635-A/42: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGTTAGT
>OF015773.1 KR 1020200137635-A/41: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTATGTAGT
>OF015772.1 KR 1020200137635-A/40: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGGTATT
>OF015771.1 KR 1020200137635-A/39: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTAGT
>OF015770.1 KR 1020200137635-A/38: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTAGT
>OF015769.1 KR 1020200137635-A/37: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTAGT
>OF015768.1 KR 1020200137635-A/36: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTTCCC
>OF015767.1 KR 1020200137635-A/35: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTGTTCCC
>OF015766.1 KR 1020200137635-A/34: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTGTCCC
>OF015765.1 KR 1020200137635-A/33: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTT
>OF015764.1 KR 1020200137635-A/32: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTT
>OF015763.1 KR 1020200137635-A/31: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTTTG
>OF015762.1 KR 1020200137635-A/30: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTT
>OF015761.1 KR 1020200137635-A/29: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTTTG
>OF015760.1 KR 1020200137635-A/28: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTATTGTG
>OF015759.1 KR 1020200137635-A/27: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTT
>OF015758.1 KR 1020200137635-A/26: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTTTG
>OF015757.1 KR 1020200137635-A/25: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGATTGTG
>OF015756.1 KR 1020200137635-A/24: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAGTGTG
>OF015755.1 KR 1020200137635-A/23: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTGTT
>OF015754.1 KR 1020200137635-A/22: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTG
>OF015753.1 KR 1020200137635-A/21: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTG
>OF015752.1 KR 1020200137635-A/20: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTG
>OF015751.1 KR 1020200137635-A/19: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTG
>OF015750.1 KR 1020200137635-A/18: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATTTA
>OF015749.1 KR 1020200137635-A/17: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATTTA
>OF015748.1 KR 1020200137635-A/16: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATTTA
>OF015747.1 KR 1020200137635-A/15: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATGTA
>OF015746.1 KR 1020200137635-A/14: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAATTTA
>OF015745.1 KR 1020200137635-A/13: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATGTA
>OF015744.1 KR 1020200137635-A/12: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATGTA
>OF015743.1 KR 1020200137635-A/11: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTCACG
>OF015742.1 KR 1020200137635-A/10: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTCACG
>OF015741.1 KR 1020200137635-A/9: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATGCACG
>OF097233.1 KR 1020200120675-A/160: OLIGONUCLEOTIDE THERAPY FOR WILSON DISEASE
TTATCTTTT
>OF014924.1 KR 1020200137634-A/55: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTT
>OF014923.1 KR 1020200137634-A/54: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTT
>OF014922.1 KR 1020200137634-A/53: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTTCTG
>OF014921.1 KR 1020200137634-A/52: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTGCTT
>OF014920.1 KR 1020200137634-A/51: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAAGTTCTG
>OF014919.1 KR 1020200137634-A/50: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
AAATTGCTG
>OF014918.1 KR 1020200137634-A/49: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTTCTT
>OF014917.1 KR 1020200137634-A/48: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTTCTT
>OF014916.1 KR 1020200137634-A/47: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTGCTT
>OF014915.1 KR 1020200137634-A/46: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTATT
>OF014914.1 KR 1020200137634-A/45: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTATT
>OF014913.1 KR 1020200137634-A/44: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATTTAGT
>OF014912.1 KR 1020200137634-A/43: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTATT
>OF014911.1 KR 1020200137634-A/42: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGTTAGT
>OF014910.1 KR 1020200137634-A/41: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTATGTAGT
>OF014909.1 KR 1020200137634-A/40: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGGTATT
>OF014908.1 KR 1020200137634-A/39: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGAGTTAGT
>OF014907.1 KR 1020200137634-A/38: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGATGTAGT
>OF014906.1 KR 1020200137634-A/37: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTAGGTAGT
>OF014905.1 KR 1020200137634-A/36: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTTTCCC
>OF014904.1 KR 1020200137634-A/35: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTGTTCCC
>OF014903.1 KR 1020200137634-A/34: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTTGTCCC
>OF014902.1 KR 1020200137634-A/33: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTT
>OF014901.1 KR 1020200137634-A/32: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTT
>OF014900.1 KR 1020200137634-A/31: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTTTG
>OF014899.1 KR 1020200137634-A/30: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTT
>OF014898.1 KR 1020200137634-A/29: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTTTG
>OF014897.1 KR 1020200137634-A/28: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTATTGTG
>OF014896.1 KR 1020200137634-A/27: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTT
>OF014895.1 KR 1020200137634-A/26: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTTTG
>OF014894.1 KR 1020200137634-A/25: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGATTGTG
>OF014893.1 KR 1020200137634-A/24: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAGTGTG
>OF014892.1 KR 1020200137634-A/23: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTGTT
>OF014891.1 KR 1020200137634-A/22: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAGTTTG
>OF014890.1 KR 1020200137634-A/21: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGATTGTG
>OF014889.1 KR 1020200137634-A/20: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAGTGTG
>OF014888.1 KR 1020200137634-A/19: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAGTGTG
>OF014887.1 KR 1020200137634-A/18: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATTTA
>OF014886.1 KR 1020200137634-A/17: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATTTA
>OF014885.1 KR 1020200137634-A/16: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATTTA
>OF014884.1 KR 1020200137634-A/15: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTTAATGTA
>OF014883.1 KR 1020200137634-A/14: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGGAATTTA
>OF014882.1 KR 1020200137634-A/13: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TGTAATGTA
>OF014881.1 KR 1020200137634-A/12: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TTGAATGTA
>OF014880.1 KR 1020200137634-A/11: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATTCACG
>OF014879.1 KR 1020200137634-A/10: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAAGTCACG
>OF014878.1 KR 1020200137634-A/9: RNA interference inducing nucleic acids suppressing noncanonical targets of microRNA and use thereof
TAATGCACG
>OF095912.1 KR 1020200115576-A/13: ANTI-TMPRSS2 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS
AAGGCGTCT
>OF013618.1 KR 1020200116308-A/6: Method for detecting polynucleotide using FRET-PAINT
AACCATACA
>OF013616.1 KR 1020200116308-A/4: Method for detecting polynucleotide using FRET-PAINT
ACTACCTCA
>OF013312.1 KR 1020200110551-A/14: Monoclonal Antibodies for detecting the structural protein antibodies against Foot and Mouth Disease Virus serotype O and using the same
CTTGCATCC
>OF013123.1 KR 1020200106761-A/7: A METHOD CODING STANDARDIZATION OF DNA AND A BIOTECHNOLOGICAL USE OF THE METHOD
GCGGTGGCG
>OF092789.1 KR 1020200110688-A/10: FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF
GCCACATCC
>OF092377.1 KR 1020200100206-A/2: DNA-ENCODED LIBRARIES HAVING ENCODING OLIGONUCLEOTIDE LINKAGES NOT READABLE BY POLYMERASES
GCAGCACCC
>OF092318.1 KR 1020200110376-A/47: ADENO-ASSOCIATED VIRUS GENE THERAPY FOR 21-HYDROXYLASE DEFICIENCY
CCACCATGG
>OF129947.1 KR 1020200135563-A/77: IMMUNOGENIC COMPOSITIONS AND VACCINES DERIVED FROM BACTERIAL SURFACE RECEPTOR PROTEINS
ATTGATGGG
>OF129883.1 KR 1020200133826-A/733: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>OF129871.1 KR 1020200133826-A/709: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129859.1 KR 1020200133826-A/685: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>OF129847.1 KR 1020200133826-A/661: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>OF129835.1 KR 1020200133826-A/637: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>OF129823.1 KR 1020200133826-A/613: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129811.1 KR 1020200133826-A/589: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GATGCATCC
>OF129799.1 KR 1020200133826-A/565: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129787.1 KR 1020200133826-A/541: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129775.1 KR 1020200133826-A/517: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>OF129763.1 KR 1020200133826-A/493: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129751.1 KR 1020200133826-A/469: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129739.1 KR 1020200133826-A/445: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129727.1 KR 1020200133826-A/421: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129715.1 KR 1020200133826-A/397: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129703.1 KR 1020200133826-A/373: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129691.1 KR 1020200133826-A/349: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129679.1 KR 1020200133826-A/325: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>OF129667.1 KR 1020200133826-A/301: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>OF129655.1 KR 1020200133826-A/277: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>OF129643.1 KR 1020200133826-A/253: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTTT
>OF091434.1 KR 1020200109338-A/1606: ALPHA-SYNUCLEIN ANTISENSE OLIGONUCLEOTIDES AND USES THEREOF
AGAGAATTG
>OF129631.1 KR 1020200133826-A/229: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>OF129619.1 KR 1020200133826-A/205: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>OF129607.1 KR 1020200133826-A/181: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TTGGGTTCT
>OF129595.1 KR 1020200133826-A/157: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGTTTCT
>OF129583.1 KR 1020200133826-A/133: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>OF129571.1 KR 1020200133826-A/109: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GCTGCATCC
>OF129559.1 KR 1020200133826-A/85: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCATCT
>OF129547.1 KR 1020200133826-A/61: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
TGGGCCTCT
>OF129535.1 KR 1020200133826-A/37: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
AAGGCGTCT
>OF129523.1 KR 1020200133826-A/13: HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS
GGTGCATCC
>OF129423.1 KR 1020200133284-A/53: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGGCAGGC
>OF129417.1 KR 1020200133284-A/47: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
GCAGCAGCA
>OF129413.1 KR 1020200133284-A/43: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
AGCAGCAGC
>OF129409.1 KR 1020200133284-A/39: OLIGONUCLEOTIDE ANALOGUES HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CAGCAGCAG
>OF125163.1 KR 1020200141461-A/93: A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN TREATING A METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA
GGTGCATCC
>OF125123.1 KR 1020200141461-A/13: A LEPTIN RECEPTOR AGONIST ANTIBODY FOR USE IN TREATING A METABOLIC DYSFUNCTION OR HYPOLEPTINEMIA
GCTGCATCC
>OF124982.1 KR 1020200135449-A/10: COMBINATION OF ANTI-HGFR ANTIBODY AND HEGFR FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS
GCTGCATCC
>OF043823.1 KR 1020200100089-A/13: BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND LEPTIN RECEPTOR AND/OR GP130, AND METHODS OF USE THEREOF
GCTGCATCC
>OF043383.1 KR 1020200096253-A/755: BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
TACACCTCC
>OF043382.1 KR 1020200096253-A/754: BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
TACACTAGC
>OF043346.1 KR 1020200096253-A/637: BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
TGGGCCTCT
>OF043327.1 KR 1020200096253-A/533: BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR, AND USES THEREOF
TGGGCCTCT
>OF042295.1 KR 1020200098528-A/98: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
GCTGCATCC
>OF042287.1 KR 1020200098528-A/78: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
GATGCATCC
>OF042279.1 KR 1020200098528-A/62: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
GCTGCATCC
>OF042271.1 KR 1020200098528-A/46: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
AAGGCGTCT
>OF042263.1 KR 1020200098528-A/30: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
GCTGCATCC
>OF042255.1 KR 1020200098528-A/14: ANTI-C5 ANTIBODY COMBINATIONS AND USES THEREOF
GCTGCATCC
>OF120536.1 KR 1020200135435-A/309: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GGTGCATCC
>OF120492.1 KR 1020200135435-A/221: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120484.1 KR 1020200135435-A/205: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120476.1 KR 1020200135435-A/189: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GATGCATCC
>OF120468.1 KR 1020200135435-A/173: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GATGCATCC
>OF120460.1 KR 1020200135435-A/157: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120452.1 KR 1020200135435-A/141: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GGTGCATCC
>OF120444.1 KR 1020200135435-A/125: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120436.1 KR 1020200135435-A/109: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120428.1 KR 1020200135435-A/93: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120420.1 KR 1020200135435-A/77: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GATGCATCC
>OF120412.1 KR 1020200135435-A/61: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF120404.1 KR 1020200135435-A/45: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
TATGCTTCC
>OF120396.1 KR 1020200135435-A/29: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GATGCATCC
>OF120388.1 KR 1020200135435-A/13: ANTI-PFRH5 ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF
GCTGCATCC
>OF081130.1 KR 1020200108002-A/13: STEROIDS AND ANTIBODY-CONJUGATES THEREOF
GGTGCATCC
>OF040657.1 KR 1020200089286-A/755: COMBINATION THERAPIES
TACACCTCC
>OF040656.1 KR 1020200089286-A/754: COMBINATION THERAPIES
TACACTAGC
>OF040620.1 KR 1020200089286-A/637: COMBINATION THERAPIES
TGGGCCTCT
>OF040601.1 KR 1020200089286-A/533: COMBINATION THERAPIES
TGGGCCTCT
>OF080881.1 KR 1020200115517-A/29: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>OF080873.1 KR 1020200115517-A/13: HUMAN ANTIBODIES TO INFLUENZA HEMAGGLUTININ
GGTGCATCC
>OF118982.1 KR 1020200134253-A/142: PHARMACEUTICAL COMBINATIONS
TGGGCCTCT
>OF118971.1 KR 1020200134253-A/131: PHARMACEUTICAL COMBINATIONS
TGGGCCTCC
>OF118957.1 KR 1020200134253-A/117: PHARMACEUTICAL COMBINATIONS
TGGGCATCC
>OF117009.1 KR 1020200128125-A/604: METHODS FOR ALTERING BODY COMPOSITION
GGTGCATCC
>OF116977.1 KR 1020200128125-A/540: METHODS FOR ALTERING BODY COMPOSITION
GGGGCAAGT
>OF116949.1 KR 1020200128125-A/484: METHODS FOR ALTERING BODY COMPOSITION
GCTGCATCC
